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8INTRODUCTION
Renal function tests are important to evaluate 
the progression of kidney disease and to 
monitor renal function during drug treatment. 
For the assessment of renal function the 
mechanisms responsible for the formation of 
urine, namely glomerular filtration, tubular 
reabsorption and tubular secretion, must 
be taken into consideration. The excretion 
of endogenous and exogenous substances 
is mainly regulated by glomerular filtration. 
Glomerular filtration rate (GFR) is considered 
the most important parameter to evaluate 
renal function and it is affected by most 
kidney diseases.
For children’s convenience it is important that 
the test to determine GFR can be performed 
in a short time window with minimal 
intervention (the total number of blood 
samples required and the blood volume at 
each sampling time have to be small). On the 
other hand it is important that the test shows 
a high accuracy. In general, tests that are most 
accurate are also those that are most elaborate 
and costly. Traditional accurate determination 
of GFR requires a lot of blood samples or a 
precise collection of urine, which is difficult in 
children. 
The aim of this thesis was to develop a simple, 
practical, convenient and accurate method 
to determine the glomerular filtration rate 
adapted to the specific requirements of 
children.      
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CHAPTER 1
DETERMINATION OF THE GLOMERULAR FILTRATION RATE IN 
CHILDREN
In this chapter the pros and cons of several 
markers for the determination of GFR 
especially in children will be described. Some 
years ago Rahn et al. published a review 
about how to assess glomerular function 
in human subjects [2]. Gaspari et al. has 
described the usefulness of several markers 
for the determination of the glomerular 
filtration rate, particularly the marker iohexol 
[3]. However, those papers did not specifically 
refer to children and in recent years new 
markers for GFR (such as cystatin C) have been 
proposed. There are no methods specially 
designed for children, most methods used 
for the determination of GFR have been 
derived from adults. However, some markers 
for GFR are more preferable in children. In 
particular, special formulae to estimate GFR 
based on creatinine concentration have been 
developed for children.
Finally it will become apparent which 
methods are accurate and practical in order to 
determine the GFR in children in either daily 
practice or in a clinical research setting.       
Glomerular Filtration Rate (GFR) is considered 
the most fundamental parameter to evaluate 
renal function in suspected renal diseases and 
to monitore renal function during treatment. 
The ideal marker for the determination of GFR 
is physiologically inert, freely filtered in the 
glomerulus and neither secreted, reabsorbed, 
synthesized, nor metabolized by the kidney.  
In addition, in case of an endogenous marker, 
a constant production rate is required.  
Several markers can be used for the  
determination of GFR: creatinine and 
cystatin C as endogenous marker, and inulin, 
radio-isotopes (125I-iothalamate, 51Cr-EDTA 
and 99mTc-DTPA) and iohexol as exogenous 
marker. Inulin, a polysaccharide, has all of the 
properties of an ideal marker and is therefore 
considered the gold standard marker [1]. 
The classic method to determine the inulin 
clearance requires an intravenous infusion 
of inulin and timed urine collections over a 
period of several hours, which makes it both 
costly and cumbersome. As a result a number 
of alternative methods and markers for the 
determination of GFR has been developed.
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METHODS FOR THE DETERMINATION OF GFR 
GFR can be determined by measuring the appearance of a marker in the urine 
(urinary clearance) or the disappearance of the marker from the blood (plasma 
clearance). 
Urinary clearance
The urinary clearance of a marker is defined as the volume of plasma from which 
the marker would have to be totally cleared to account for its excretion in the urine 
during a certain period of time. It always requires the measurement of the urinary 
excretion rate. The urinary clearance is calculated by dividing the urinary excretion 
rate of the marker by its plasma concentration (Table I). Both endogenous and 
exogenous markers can be used for the determination of the urinary clearance. For 
endogenous markers 3 to 4 accurately timed urine samples are collected [1]. The 
exogenous marker is administered by continuous intravenous infusion until a steady 
state concentration has been reached. After the equilibration period also 3 to 4 
accurately timed urine samples are collected [1]. During the equilibration and the 
Table I. Methods for determination of GFR
Clearance Type of marker Method Urine collection Plasma sampling  Calculation of GFR (mL/min)
Urinary clearance endogenous - yes yes 
 exogenous continuous infusion yes yes  
 exogenous single injection yes yes 
Plasma clearance exogenous continuous infusion no yes 
 exogenous single injection no yes   
GFR can be determined by measuring the excretion of a marker in the urine (urinary clearance) or the 
disappearance of the marker from the blood (plasma clearance). For determination of the urinary clearance 
both endogenous and exogenous markers for GFR can be used, while for determination of the plasma 
clearance only exogenous markers can be applied.   
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period of urine collection diuresis is induced 
to maintain a high urine flow rate. Critical 
aspects of this method are the required time 
for equilibration of the exogenous filtration 
marker in body fluids, an adequate urine flow 
rate for complete emptying of the bladder, an 
accurate measurement of the urine volume for 
each clearance period and a precise recording 
of the duration of the urine collection period. 
In infants and young children collection 
of timed urinary specimens is difficult and 
requires bladder catheterization. 
Plasma clearance
Instead of measuring the excretion of a marker 
in the urine, one can also measure the rate of 
disappearance of the marker from the plasma, 
which is indicated as the plasma clearance. 
This method can only be performed with an 
exogenous marker. The plasma clearance of 
an exogenous marker can be measured by use 
of either a continuous intravenous infusion 
or a single bolus injection. The continuous 
infusion method is based on the concept that 
when the plasma concentration of the marker 
is constant (steady state concentration) and 
the volume of distribution is saturated with 
the marker (state of equilibration), the rate of 
excretion equals the rate of infusion [1, 4]. GFR 
can be calculated from the infusion rate, the 
concentration of the marker in the infusate 
and the plasma concentration of the marker 
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U: concentration of the marker in urine (mg/mL); V: urine flow rate (mL/min); P: concentration of the marker in plasma 
(mg/mL); I: concentration of the marker in infusate (mg/mL); R: infusion rate (mL/min); D: dose (mg); AUC: Area Under the 
Curve (min*mg/mL) 
U x V
P
U x V
P
U x V
P
I x R
P
D
AUC
Table I. Methods for determination of GFR
Clearance Type of marker Method Urine collection Plasma sampling  Calculation of GFR (mL/min)
Urinary clearance endogenous - yes yes 
 exogenous continuous infusion yes yes  
 exogenous single injection yes yes 
Plasma clearance exogenous continuous infusion no yes 
 exogenous single injection no yes   
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(Table I). The time to reach a steady state concentration of the marker is critical. 
GFR is overestimated if a steady state concentration has not yet been reached. 
In general the steady state concentration of a drug (90% of the steady state) is 
reached in 3.3 half-lives [5]. A loading dose can be given to reach the steady state 
concentration more rapidly. Calculation of an appropriate infusion rate and its 
matching loading dose is important for reaching equilibration in a short time [6]. 
With the single injection method, a bolus injection of the marker is administered and 
blood samples are collected to construct a plasma concentration-time-decay-curve. 
The plasma clearance of the marker is calculated from the dose and the Area Under  
the concentration-time Curve (AUC), using a classical pharmacokinetic approach 
[1] (Table I). For practical and convenient application in children it is important that 
the number of blood samples is reduced to a minimum to construct the plasma 
concentration-time curve. Critical aspects of the single injection method are the pre-
analytical process and the pharmacokinetic analysis. According to the pre-analytical 
process it is important to know the exact administered dose of the marker and to note 
the exact time of blood sampling. Several computer programs can be used for the 
pharmacokinetic analysis of the data, however one has to realize that the programs 
always produce a value and it is up to the operator to evaluate if this value is correct.    
   
MARKERS FOR THE DETERMINATION OF GFR
1. Exogenous markers
INULIN
Inulin is a polymer of fructose with a molecular weight of about 5200 Da (Table II) and 
has all of the properties of an ideal filtration marker. The suitability of inulin as a marker 
for GFR has been described by Smith in 1951 [7]. Because of the poor solubility of inulin 
and the need to heat it before administration, an inulin analogue has been developed. 
This analogue, called polyfructosan-S (sinistrin, Inutest®), is more soluble and has a 
molecular weight of about 3500 Da. The clearance and the volume of distribution of 
this inulin analogue do not differ from that of inulin [8].
Inulin can be analyzed in urine and plasma by a classical colorimetric reaction (anthrone 
method) [9], or by an enzymatic method [10-13]. Both methods are based on the hydrolysis 
of inulin to fructose. Glucose and other carbohydrates interfere with the anthrone method 
and have to be removed before analysis. The enzymatic assay shows less interference.
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URINARY CLEARANCE OF INULIN
The urinary clearance of inulin is regarded to 
be the gold standard for the determination 
of GFR. Due to the disadvantages mentioned 
before this method is not commonly applied 
in clinical practice in children. 
PLASMA CLEARANCE OF INULIN
A high degree of correlation between the 
plasma clearance by continuous infusion and 
the urinary clearance of inulin in children was 
found [14-16]. The time to reach a steady state 
concentration is critical for the continuous 
infusion method. An equilibration period of 
one to three hours is commonly used but 
there are data indicating that a period of more 
than 12 hours may be required for complete 
equilibration of inulin in the extra cellular 
space [15]. In newborns a 24-hour infusion 
of inulin is necessary since they have a low 
GFR (reference value for GFR in newborns 
< 2 weeks: 25 - 35 mL/min/1.73m2)  
and a relatively large extra cellular fluid 
compartment [17, 18].  
The inulin single injection method is based 
on the pharmacokinetic concept that the 
clearance can be calculated from the dose and 
the AUC as explained before (Table I). For the 
determination of the inulin clearance with the 
single injection method, a bolus injection of 
inulin is administered and blood samples are 
collected up to 180 - 240 min after injection. 
Usually a two-compartment model is applied 
to construct the plasma concentration-
time curve, but a three-compartment model 
has also been proposed [19, 20]. 
In two published studies, the plasma clearance 
by the single injection method was compared 
with the urinary clearance of inulin in children 
[21, 22]. A good correlation between the GFR 
determined by the single injection method 
and the GFR measured by means of the 
urinary clearance was found (r=0.82), however 
the number of children studied was small 
(n=13) [22]. 
We compared the single injection method 
with the continuous infusion method to 
determine the plasma clearance of inulin in 24 
children. For the single injection method 5000 
mg/m2 of inulin was administered as bolus 
injection and blood samples were drawn at 10, 
30, 90 and 240 minutes after administration. 
For the continuous infusion method inulin 
was started overnight and blood samples 
were collected the next day. The inulin plasma 
clearance determined by the single injection 
method was on average 9.7 mL/min/1.73m2 
higher than the clearance determined with 
the continuous infusion method (95% CI: 5.3; 
14.2). The difference between both methods 
was smaller at lower GFR [23]. 
For practical and convenient application in 
children it is important that the number of 
blood samples is reduced to a minimum to 
construct the required plasma concentration-
time curve. A reduction of the total number 
of blood samples from 12 to 7 in children has 
been published [24]. We described optimal 
sampling strategies for the inulin single 
injection method with at least 1 blood sample 
in children [25].   
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RADIO-ISOTOPES
A number of radionuclide-labeled compounds, including 125I-iothalamate,  
51Cr-EthyleneDiamineTetra-Acetic acid (51Cr-EDTA) and 99mTc-DiethyleneThiaminePenta-
Acetic acid (99mTc-DTPA), can be used to determine GFR (Table II). The advantage 
of using radionuclides as marker for GFR is that they are easy to administer, can 
be measured with great accuracy, and are relatively cheap. Drawbacks related to 
radiation exposure and safety have led to a limited use of these markers in children. 
Especially the use of infusion of radionuclides for several hours is undesirable and 
therefore for these markers single injection methods have been developed, as well. 
Table II. Markers for the determination of GFR
Type of marker Marker Molecular weight  
  (Da) 
exogenous inulin 5200 
 125 or 131I-iothalamate 614   
  (iothalamate)  
 51Cr-EDTA 292  
  (EDTA)
 
 99mTc-DTPA 393  
  (DTPA)
 iohexol 821  
endogenous creatinine 113  
   
 cystatin C 13300 
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IOTHALAMATE
The marker iothalamate has a molecular 
weight of 614 Da and is labeled with 125Iodine 
or 131Iodine. Both urinary and plasma clearance 
of labeled iothalamate can be determined. 
The plasma clearance of 125I-iothalamate with 
single injection of the marker correlated 
closely with the urinary clearance of inulin 
in children, however an overestimation 
of on average 12% was found and the 
difference between the methods increased 
with decreasing GFR [26]. Possibly the total 
sampling period of 60 minutes for the 125I-
iothalamate single injection method was too 
short. The urinary clearance of 131I-iothalamate 
agreed well with the urinary clearance of 
inulin in a small group of children (r=0.995; 
30 studies in 10 children) and had a small 
standard error [27]. This result is in contrast 
with the observation of Rahn et al. that the 
urinary clearance of iothalamate in adults 
exceeded the urinary clearance of inulin, 
which suggested that tubular secretion of 
iothalamate occurs [2]. It is unclear whether 
these conflicting results can be explained by 
differences in age or have other reasons.
A single injection method with subcutaneous 
administration of the marker was developed 
for the determination of the urinary clearance 
of 125I-iothalamate in children and had a mean 
coefficient of variation of less than 15% [28].    
Unlabeled iothalamate can also be used for 
determination of GFR. The concentration of 
unlabeled iothalamate in serum and urine 
is measured by High Performance Liquid 
Chromotography (HPCL) or X-ray fluorescence. 
Mak et al. reported that there was no 
significant difference between the plasma and 
urinary clearance of unlabeled iothalamate 
when both were measured simultaneously 
in children with a renal transplant [16]. 
Sharma et al. showed that there was no 
difference between the plasma clearance of 
subcutaneously infused unlabeled iothalamate 
and the urinary clearance of 125I-iothalamate in 
children and young adults [29]. A mean ratio 
(plasma clearance / urinary clearance) of 0.99 
(limits of agreement 0.83-1.23) was found. 
EDTA
Several studies have been reported on the use 
of EDTA (molecular weight 292 Da) labeled 
with 51Cr for the determination of GFR in 
children [30-43]. In most cases the plasma 
clearance of 51Cr-EDTA with single injection of 
the marker was determined. The results from 
studies comparing the 51Cr-EDTA clearance 
with the clearance of other markers in children 
are presented in Table III. The plasma clearance 
of 51Cr-EDTA with single injection agreed 
well with the plasma clearance of inulin if 
a two-compartment analysis was applied. 
With one-compartment analysis the AUC was 
underestimated and as a consequence the 
clearance was overestimated.  
Optimalisation of the single injection method 
for 51Cr-EDTA in children has been described 
by several authors and resulted in reduction of 
the required number of blood samples to even 
1 sample [31, 36, 39, 40]. It is possible to use 
capillary instead of venous blood samples for 
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Table III. Results of studies comparing the 51Cr-EDTA clearance 
with a reference clearance in children
Author n Population Reference method Method for determination  Results Range of GFR
    of 51Cr-EDTA clearance
Aperia et al. [30]  patients with renal diseases plasma clearance of plasma clearance with   one patient with GFR 
   inulin with single injection single injection  < 50 mL/min/1.73m2
 37   one-compartment analysis significant overestimation  
 21   two-compartment analysis no significant differences  
Gibb et al. [37] 11 diabetic patients urinary clearance of inulin  urinary clearance with  underestimation with a mean  no patients with GFR 
   with continuous infusion continuous infusion of 7.9 mL/min/1.73m2 < 50 mL/min/1.73m2
Mak et al. [16] 13 patients with renal transplant plasma clearance of inulin with  plasma clearance with  mean ratio of 1.14 ± 0.09,  8 - 70 mL/min
 (15 tests)  continuous infusion single injection not significant
    one-compartment analysis 
   plasma clearance of iothalamate   mean ratio of 1.15 ± 0.08,
   with continuous infusion  not significant
Vögeli et al. [43] 28 patients with various GFR urinary clearance of inulin  plasma clearance with  good agreement (y = 0.991x) 8 - 212 mL/min/1.73m2 
   with continuous infusion single injection
    compartment analysis 
    not mentioned
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this method [33]. However, no comparison with the clearance of other markers  
(i.e. inulin) was made for these optimized methods and, in the case of application of 
a one-compartment analysis, it is very likely that the GFR is overestimated.
          
DTPA
99mTc-DTPA is a chelate of DTPA and 99mTc and commonly used in renal imaging. This 
compound can also be used to determine the GFR (Table II). The plasma clearance 
of 99mTc-DTPA determined by single injection agreed well with the plasma clearance 
of 51Cr-EDTA in children with reflux nephropathy (n=154) [44]. Rodman et al. 
reported that binding of DTPA to serum compounds (i.e. proteins) is a confounding 
factor for the determination of the clearance [45]. In 17 children with cancer the 
plasma clearance of 99mTc-DTPA was determined with and without ultrafiltration 
of the serum samples. The median clearance of 99mTc-DTPA from unfiltrated serum 
was significantly lower than the clearance with ultrafiltrated serum. However, no 
comparison with a reference clearance (i.e. urinary clearance of inulin) was made. 
Methods based on renography have been described to determine the GFR using 
99mTc-DTPA with the percentage renal uptake or the slope from the renogram 
as predictors for GFR [46-52]. The advantage of these methods is that no blood 
samples are required and that additional information regarding the anatomy of 
renal function can be obtained. 
IOHEXOL
Since the use of radiolabeled markers for GFR in children is limited, new unlabeled 
contrast media have been introduced to determine GFR. Iohexol is a low osmolar 
non-ionic contrast medium, which is used for angiography and urography. It has 
a molecular weight of 821 Da, is distributed in the extracellular volume [53] and 
eliminated from plasma by glomerular filtration [54]. Iohexol can be analyzed in 
urine and plasma by HPCL [54] or by X-ray fluorescence [55]. The HPLC-analysis of 
iohexol is complex, since there are two isomers of iohexol with different retention 
times [55, 56]. For practical purpose usually the plasma concentration of one 
iohexol isomer is used for calculation of GFR.     
A single bolus injection method with drawing one blood sample and applying an 
empirical formula for the distribution volume of iohexol has been developed for the 
determination of the plasma clearance of iohexol in infants and children [53, 57]. 
Usually a two-compartment model is used to construct the plasma concentration-
time curve for iohexol, but in several studies a one-compartment model with a 
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correction factor for the overestimation of GFR 
has been applied [53, 58] and even a three-
compartment model has been suggested [59]. 
Lindblad et al. compared the plasma clearance 
of iohexol with the plasma (n=20) and urinary 
(n=54) clearance of inulin in children and 
young adults [60]. A correlation coefficient 
of 0.81 and 0.86, respectively was found. The 
agreement between the plasma clearance of 
iohexol and 99mTc-DTPA was investigated in 
infants and children [57, 58, 61]. The plasma 
clearance of iohexol was not significantly 
different from the plasma clearance of 
99mTc-DTPA. 
Stake et al. studied the effect of iohexol on 
renal function in 10 children [58]. No change 
in GFR was detected after administration of a 
standard dose of iohexol, however the number 
of patients in the study was small and the 
effect of iohexol on renal function was studied 
only at the day of administration.
2. Endogenous markers
CREATININE
Creatinine has a molecular weight of 113 Da 
and is a metabolic product of creatine and 
phosphocreatine in the muscle. Its production 
is proportional to the total muscle mass. 
This leads to a variation in serum creatinine 
concentration across age, gender, race, 
nutritional status and body composition. 
Creatinine is not an ideal marker for GFR 
because it is not only freely filtered by the 
glomerulus, but also secreted by the proximal 
tubule. The extent of tubular secretion 
of creatinine is not constant and shows 
interpatient and intrapatient variability, 
which makes it impossible to use a constant 
correction factor for tubular secretion [62].  
The proportion of total renal creatinine 
excretion due to tubular secretion increases 
with decreasing renal function. As a 
consequence the GFR based on the plasma 
creatinine concentration is overestimated, 
particularly at lower GFR. The tubular secretion 
of creatinine can be inhibited by several 
compounds (such as cimetidine), which are 
secreted by the same pathway [63-65]. 
The urinary clearance of creatinine can be 
determined or GFR can be estimated by a 
formula based on the plasma concentration of 
creatinine. The former method is not directly 
affected by differences in creatinine production. 
However, accurate collection of the required 
timed urinary samples is difficult. Simultaneous 
determination of the urinary clearance of 
creatinine and inulin in children showed a good 
agreement, but an overestimation of inulin 
clearance was found especially at low levels 
of GFR [66, 67]. This was to be expected, since 
tubular secretion of creatinine increases with 
decreasing renal function.
FORMULAE TO ESTIMATE GFR BASED ON CREATININE 
PLASMA CONCENTRATION
A number of formulae, including the 
reciprocal plasma concentration of creatinine, 
has been developed to estimate GFR. Variation 
in creatinine production due to age- and sex-
related differences in muscle mass has been 
incorporated in these formulae. For adults 
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the formula of Cockroft and Gault is widely used [68]. However Paap et al. showed 
that this formula couldn’t be applied in children [69]. The best-known formulae for 
children are the formula of Schwartz et al. [70] and the formula of Counahan et al. 
[71] (Table IV). Both formulae are based on a constant (k) multiplied by the child’s 
body height (BH, cm) divided by the plasma creatinine concentration (Pcr, μmol/L):
The difference between k in the formula of Schwartz (k = 48.7) and in the Counahan 
formula (k = 38) has been attributed to the use of different assays to measure the 
creatinine concentration and the difference in the reference method. Schwartz et al. 
used the urinary clearance of creatinine, while Counahan et al. applied the plasma 
clearance of 51Cr-EDTA. Subsequently Schwartz et al. defined various values of k for 
infants and children of different ages, since the relationship between muscle mass 
and body height changes with age [72-74]. Morris et al. derived a formula closely 
related to the formula of Counahan (modified formula of Counahan with k = 40 for 
Pcr in μmol/L, Table IV) [75]. This formula is commonly used in clinical practice and 
inadvertently indicated as the ‘Schwartz formula’.   
Seikaly et al. reported that the GFR estimated by the formula of Schwartz 
overestimated the urinary clearance of 125I-iothalamate (176 studies in 133 children; 
range of overestimation: 0.1 - 164%) and that this overestimation was larger with 
decreasing GFR [76]. This is not surprising since the formula of Schwartz is based 
on the creatinine clearance, which overestimates GFR especially at low GFR.  Berg 
et al. reported that the GFR estimated by the formula according to Morris et 
al. was inaccurate to follow the renal function in pediatric patients with a renal 
transplant and treated with cyclosporine, especially during the first 2 years after 
transplantation [77]. This finding was most likely due to changes in habitus and 
increased creatinine secretion caused by cyclosporine.
It is important to realize that the formulae for GFR estimation should not be used 
in patients with body disproportions, reduced muscle mass or muscle diseases. In 
critically ill children of a pediatric intensive care unit the estimated GFR (formula of 
Schwartz) correlated significantly with the urinary clearance of creatinine (n=100). 
However, the discrepancy between the two methods was larger than 50% in 36 of 
100 patients [78]. The most plausible reason for this finding was that many children 
in the pediatric intensive care unit had abnormally low muscle mass as a result of 
chronic disease or malnutrition. 
GFR(mL/min/1.73m2) =
k x BH
Pcr
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Skinner et al. studied the relationship 
between the GFR estimated by formulae 
(Schwartz, Counahan and Morris) and the 
plasma clearance of 51Cr-EDTA in children 
with tumours, who were treated with 
chemotherapy [79]. They found extremely 
wide limits of agreement for all the three 
formulae. The bias was smallest for the formula 
according to Morris et al.   
Léger et al. studied the relation between 
the plasma concentration of creatinine 
and the plasma clearance of 51Cr-EDTA in 
children (n=64) and applied a population 
pharmacokinetic approach [80]. The derived 
algorithm to estimate the plasma clearance of 
51Cr-EDTA included body weight, square body 
height and plasma creatinine concentration 
(Table IV) and was tested in 33 children 
with kidney diseases. A good predictive 
performance was found.         
Recently, Hellerstein et al. compared the 
formula of Léger et al. with the formula based 
on the ratio of the child’s body height and 
the plasma creatinine concentration in 151 
children [81]. The optimal value for k was 
determined locally (k = 44 for girls and boys 
younger than 13 years and k = 52 for boys 
older than 13 years). The formula of Léger et 
al. was not superior to the GFR calculated 
with k = 44 or 52. However, in the study of 
Hellerstein et al. the values for k were derived 
from and tested in the same data set, which is 
statistically incorrect. 
We evaluated the predictive performance of 
several formulae by comparing them with the 
inulin plasma clearance (n=48, 5 - 18 years of 
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Table IV. Formulae to estimate GFR based on creatinine concentration
Author Formula for estimation of GFR Reference clearance 
Counahan et al. [71]a  plasma clearance of 51Cr-EDTA  
    
Léger et al. [80]b  plasma clearance of 51Cr-EDTA 
Morris et al. [75]a  plasma clearance of 51Cr-EDTA 
Schwartz et al. [70]a  urinary clearance of creatinine 
BH: body height (cm); Pcr: plasma creatinine concentration (µmol/L)
aGFR in mL/min/1.73m2
bGFR in mL/min
38 x BH
Pcr
56.7 x Weight + 0.142 x BH2
Pcr
40 x BH
Pcr
48.7 x BH
Pcr
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age) [82]. The formulae with k= 40 (Morris) or k = 41.2 estimated GFR well (bias< 5%; 
precision: 25%). The formula according to Léger et al. overestimated the inulin 
plasma clearance.
One has to realize that the formulae to estimate GFR can only be applied for clinical 
daily practice. The formulae are too imprecise for an accurate determination of GFR 
as desired in a research setting. Pierrat et al. reported an overestimation of 20-25% 
for the formula according to Schwartz et al. [83]. We found that the difference 
between estimated GFR and inulin plasma clearance was larger than 10 mL/min/
1.73m2 in more than 40% of the patients [82]. Therefore the formulae cannot replace 
the classical method for determination of GFR.
CYSTATIN C
Cystatin C is a small cationic protein, which inhibits cysteine proteinase, and has 
a molecular weight of 13.3 kDa. Cystatin C is produced by all nucleated cells at 
a constant rate and is freely filtered by the glomerulus. Subsequently it is not 
secreted in the tubulus but mainly reabsorbed by tubular epithelial cells and 
catabolized completely [84, 85]. 
It has been reported that the plasma concentration of cystatin C was independent 
of gender [86, 87] and constant from 1 year of age [88-93]. However, Harmoinen 
et al. showed that children between 1 and 3 years in age had a slightly but 
significantly higher cystatin C plasma concentration than older children and 
proposed a reference interval for children from 3-16 years and younger children 
[94]. This was recently confirmed by Fischbach et al. [95]. Reference values for 
cystatin C in infants (< 1 year of age) have also been reported [90, 94, 96]. 
Elevated cystatin C concentrations have been reported for children with a renal 
transplant, which may be attributed to the use of (a large dose of ) glucocorticoids 
[97-101]. The glucocorticoid-induced increase in cystatin C can probably be 
attributed to a promoter-mediated increase in transcription of the cystatin C gene. 
For this reason it has been suggested that specific reference intervals for patients 
on glucocorticoid therapy are needed [99, 100]. 
It has been reported that the concentration of cystatin C in patients with various 
types of cancer was increased, irrespective of renal function [102]. However, it was 
not quite clear whether the increase in cystatin C concentration was attributable to 
an increased production rate or to a decreased elimination [102, 103]. Furthermore, 
thyroid dysfunction has also an impact on plasma cystatin C concentration [104, 
105]. A higher and a lower cystatin C concentration were found in hyperthyroid 
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and hypothyroid patients, respectively. A 
likely explanation for this founding is that 
the production rate of cystatin C is affected 
by thyroid dysfunction, possibly due to a 
metabolic-rate-mediated mechanism [105]. 
Several immunoassays have been developed 
for the analysis of cystatin C in plasma or 
serum. The most commonly used assays are 
the Particle-Enhanced Turbidimetric Immuno-
Assay (PETIA) and the Particle-Enhanced 
Nephelometric Immuno-Assay (PENIA). 
These methods are based on the reaction 
between cystatin C antibodies and cystatin 
C in the sample. Cystatin C concentrations 
measured by PENIA seem to be slightly lower 
(about 30%) compared with PETIA [87, 94]. 
The use of different assays to measure cystatin 
C concentration and the lack of a standard 
method for calibration make a direct comparison 
between the methods difficult [87, 106]. 
The reciprocal of the plasma cystatin C 
concentration has been proposed as a 
parameter for GFR. The relationship between 
the reciprocal of the cystatin C concentration 
and the reference clearance in children are 
reported in Table V.  
Several studies have been performed to 
evaluate the usefulness of cystatin C to 
estimate GFR [88, 91, 93, 107-114]. In general a 
better correlation was found for the reciprocal 
of plasma cystatin C concentration to the 
reference GFR than for the reciprocal of 
plasma creatinine concentration. However, 
in two papers a slightly lower correlation 
coefficient was reported [108, 109]. The finding 
of a higher correlation coefficient for cystatin 
C is not surprising, since the reciprocal of 
creatinine concentration alone is not the 
proper parameter for GFR. Filler et al. corrected 
the creatinine concentration for age and 
muscle mass and compared the correlation 
of the reciprocal of cystatin C concentration 
and the GFR estimated by the formula of 
Schwartz with the plasma clearance of radio-
isotopes [93]. In that study a similar correlation 
coefficient was found for the reciprocal of 
cystatin C concentration compared with the 
GFR estimated by the formula of Schwartz 
and the areas under the receiver-operating 
characteristic curve were not significantly 
different. 
An algorithm for cystatin C to estimate GFR 
was developed and tested in 101 children [88]. 
The mean difference between the methods 
was 2.37 mL/min/1.73 m2 with + 46.4 and 
- 41.6 mL/min/1.73 m2 as limits of agreement 
(mean difference ± 1.96 SD). The algorithm 
based on cystatin plasma concentration 
was not very accurate to estimate the GFR. 
In an additional study GFR estimated by the 
algorithm for cystatin C was compared with 
the 24-hour creatinine clearance in children, 
who recently received a kidney transplant 
(n=24) [115]. The mean GFR for cystatin C  
was 40% below the value based on the  
24-hour creatinine clearance, which could be 
explained by an increased concentration of 
cystatin C in patients with a renal transplant 
due to the use of glucocorticoids. Filler et al. 
derived a formula to estimate GFR from serum 
CHAPTER 1 Determination of the glomerular filtration rate in children 
see pages 30 - 39 for references
26
Table V. Relationship of the reciprocal cystatin C concentration 
and the reference clearance in children
Author Number of  Age (years) Population Reference clearance GFR Method   Correlation (r) 
 patients  patients with  (mL/min/1.73m2) for analysis  
Bökenkamp et al. [88]  83 11.2 ± 0.5 various disorders inulin clearance 81.0 ± 4.5 PETIA 0.88 
  (mean ± sd)   (mean ± sd)
Filler et al. [89] 381 12.1 ± 4.8 various renal disorders plasma clearance of 51Cr-EDTA 12 - 211  PETIA 0.64
  (mean ± sd)   (range)
Filler et al. [93] 225 11.2 ± 4.5 various renal disorders plasma clearance of 51Cr-EDTA not mentioned PENIA 0.765
  (mean ± sd)  (n=127)
    plasma clearance of 99mTc-DTPA 
    (n=98)
Filler et al. [107] 25 12.8 ± 4.2 renal transplant plasma clearance of 99mTc-DTPA  39 - 123 PENIA 0.85
 (28 tests) (mean ± sd)   (range)
Helin et al. [91]  69 1 - 16  not mentioned plasma clearance of 51Cr-EDTA  not mentioned PETIA 0.83 
  (range)     (0.56 normal GFR, n=56)
       (0.75 reduced GFR, n=13)
Kilpatrick et al. [119]  64 0.25 - 18 various disorders plasma clearance of 51Cr-EDTA  8 - 172 PENIA 0.81
  (77 tests) (range)   (range)  (0.56 high GFR)
       (0.83 low GFR)
Krieser et al. [108] 19 8.35 - 19.1 renal transplant plasma clearance of 99mTc-DTPA not mentioned PETIA 0.76
 (28 tests) (range)
Martini et al. [120] 99 1.0 - 17.9 various disorders urinary clearance of inulin 19 - 179 PETIA 0.64
  (range)   (range) 
Samyn et al. [121] 62 0.3 - 18.6 liver diseases plasma clearance of 51Cr-EDTA 28 – 270 PENIA 0.78
 (87 tests) (range)   (range)
Stickle et al. [109] 67 1.8 - 18.8 various renal disorders plasma clearance of inulin not mentioned PETIA 0.77 (n=26, 4 - 12 years)
  (range)     0.87 (n=34, 12 - 19 years)
Willems et al. [110] 66 1.3 - 21.9 various renal disorders plasma clearance of inulin 7 - 145 PENIA 0.937
  (range)   (range)  
Ylinen et al. [111] 52 2 - 16 various renal disorders plasma clearance of 51Cr-EDTA  < 89 (n=19) PETIA 0.89
  (range)  
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cystatin C concentration and compared that formula with the formula of Schwartz 
(n=536; 1.0 – 18.0 years of age) [116]. The cystatin C-based formula showed a better 
performance than the formula of Schwartz, however it was not clear whether the 
formula was derived from and tested in the same data set.   
Hellerstein et al. studied whether the ratio of urinary cystatin C to urinary creatinine 
could serve as parameter for GFR (n=82; 6.1 - 21.3 years of age) [117]. They 
concluded that the ratio was a reliable screening tool for detecting decreased GFR 
in children.  
Recently, Podracka et al. compared the intra-individual variation of cystatin C and 
creatinine concentration in 20 children with an organ transplant [118]. The mean 
coefficient of variation was significantly lower for serum creatinine (7.7 ± 4.2%) 
than for cystatin C (10.3 ± 4.9%). However, after excluding patients with bladder 
augmentation the difference was no longer significant.
CONCLUSIONS
GFR is considered the most relevant parameter to evaluate renal function. Several 
markers are available to determine the GFR in children. It would be ideal if GFR 
could be determined accurately by a simple measurement of an endogenous 
marker, for example creatinine. However, creatinine is not an ideal filtration 
marker. Estimation of the GFR in children by a formula based on the creatinine 
concentration and the body height is commonly used in daily clinical practice. 
The formula according to Morris et aI.with k = 40 showed a good predictive 
performance for rough estimation of GFR in children [75]. In general, the formulae 
based on plasma creatinine concentration provide an estimate of GFR that is 
accurate enough for general clinical purposes. However, it is important to realize 
that these formulae could not be used in patients with body disproportions, 
reduced muscle mass or muscle diseases. 
Cystatin C, a recently proposed endogenous marker, may also be useful 
to estimate GFR in daily practice. An advantage of this marker is that the 
production rate of cystatin C is less altered by nonrenal factors than the 
production of creatinine. However, it can be concluded from the studies 
discussed herefore that cystatin C is not a better marker for GFR than creatinine. 
In addition, the measurement of cystatin C concentration is expensive and 
creatinine assays are already applied routinely for many years. Therefore the  
use of cystatin C in daily practice is limited.   
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For the determination of GFR in a clinical 
research setting a more accurate method is 
required: the urinary or plasma clearance of an 
exogenous marker should be measured. Inulin, 
a polysaccharide, is regarded as the gold 
standard marker and the urinary clearance 
of inulin with continuous infusion as the 
standard reference method to determine GFR.  
Disadvantages of determination of the 
urinary clearance are that this method is 
time-consuming, inconvenient to the patient 
and that the collection of timed urinary 
specimens is difficult and requires bladder 
catheterization, especially in infants and 
young children. Determination of the plasma 
clearance of a marker is an alternative method. 
The plasma clearance of an exogenous marker 
can be determined by either continuous 
infusion or single injection of the marker. 
In practice determination of the plasma 
clearance of inulin with continuous infusion is 
more complicated and time-consuming than 
the single injection method. The inulin single 
injection method becomes more practical and 
convenient since optimal sampling strategies 
have been developed. One should realize that 
the use of such strategies requires advanced 
pharmacokinetic software and correct 
interpretation. 
In several papers alternative markers for 
GFR have been compared with inulin. The 
radiolabeled marker 51Cr-EDTA has been 
investigated extensively in children. For this 
marker simplified methods with one blood 
sample have been described, however these 
methods have not been compared with the 
urinary or plasma clearance of inulin and 
no optimal sampling strategies have been 
developed. Although the plasma clearance 
of 51Cr-EDTA with single injection is a good 
alternative for the plasma clearance of inulin, 
its use in children is restricted due to radiation 
exposure. The marker iohexol does not exhibit 
the disadvantage of radiation exposure, but 
the experience with this marker in children is 
limited. Furthermore, the analytical procedure 
is cumbersome.  
In conclusion, estimation of GFR in children 
by a formula based on creatinine plasma 
concentration and body height can be 
used for daily practice. Inulin is, despite it 
is relatively expensive, still the marker of 
choice to determine GFR in children in a 
research setting. Determination of the plasma 
clearance of inulin is preferred to the urinary 
clearance, as timed urine collection in children 
is difficult. The single injection method with 
a sparse sampling scheme in combination 
with adequate pharmacokinetic software 
is equivalent to the more cumbersome 
continuous infusion method for determination 
of the inulin plasma clearance.
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estimates of clearance were generated using 
the derived population parameters and 
concentrations at 2-4 sampling times. Bayesian 
estimates of clearance were compared with 
the individual reference values of clearance.  
The strategies with samples taken at 
10 / 30 / 90 / 240 min, 10 / 30 / 240 min, 
10 / 90 / 240 min, 30 / 90 / 240 min and 
90 / 240 min produced a good prediction of 
inulin clearance (bias < 3% and not significantly 
different from zero, imprecision < 15%). 
Strategies with two to four samples including 
a sample at 240 min after administration 
of inulin produce an accurate prediction of 
inulin clearance in pediatric patients using the 
inulin single injection method. Even 1 blood 
sample at 240 min showed an acceptable 
performance. The proposed strategies are 
practical and convenient to children, and 
reduce repetitive blood sampling without 
compromising accuracy.
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ABSTRACT
Glomerular filtration rate in patients can 
be determined by estimating the plasma 
clearance of inulin with the single injection 
method. With this method a single bolus 
injection of inulin is administered and several 
blood samples are collected. For practical 
and convenient application of this method in 
children it is important that a minimal number 
of samples is drawn. The aim of this study was 
to develop and validate sampling strategies 
with a reduced number of samples for reliable 
prediction of inulin clearance in pediatric 
patients using the inulin single bolus injection 
method.
Complete inulin plasma concentration-time 
curves of 154 patients were divided in an 
index (n=100) and validation set (n=54). A 
population pharmacokinetic model was 
developed for the index set. Optimal sampling 
times were selected based on D-optimality 
theory. For the validation set Bayesian 
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INTRODUCTION
Measurement of renal function, i.e. Glomerular Filtration Rate (GFR), is essential for 
evaluating suspected renal diseases and for studying changes in renal function 
in patients with renal failure. The ideal marker is freely filtered by the glomerulus, 
not reabsorbed, secreted or metabolized by the kidney, physiologically inert and 
does not alter renal function. Inulin, an exogenous marker, is such a marker and 
its renal clearance during continuous intravenous infusion is regarded as the gold 
standard for measuring GFR in children [1]. However, this method is complex, time 
consuming, invasive and requires urine collection. For these reasons the renal 
inulin clearance is not commonly used in clinical routine. An alternative method, 
which can be performed without collection of urine, is the determination of plasma 
clearance of inulin. The plasma clearance of inulin can be measured by use of either 
a continuous intravenous infusion or a single bolus injection. The former method 
is more accurate but time-consuming because a steady-state-situation has to be 
achieved [1]. With the latter method a bolus injection of inulin is administered 
and 10 to 12 serial blood samples are withdrawn for the construction of a plasma 
concentration-time-decay-curve. Adequate results have been reported using 
this method in adults [2, 3]. However, for practical and convenient application in 
children it is important that the number of blood samples is minimized. 
The aim of this study was to design and validate an optimal sampling strategy 
with a reduced number of samples for reliable estimation of the inulin clearance in 
pediatric patients with renal disorders using the inulin single injection method.
METHODS
Patients
The development and validation of the optimal sampling strategies was performed 
using data, which were collected during routine determination of renal function 
in 154 pediatric patients treated at the University Hospitals of Rotterdam and 
Nijmegen, between June 1994 and June 1997. Twenty-six children were seen in 
the follow-up of a hemolytic uremic syndrome. The other children were known 
for impaired renal function due to a variety of renal and acquired diseases. 
Demographic parameters and pathophysiological characteristics of the patients are 
summarized in Table I.
Table I. Patient characteristics of the full, index and validation set1 
  Full data set  Index set Validation set
Patients 154 100 54
 male 96 63 33
 female 58 37 21
Age (y) 9.0 (1.0-21.0) 10.0 (1.0-20.0) 6.5 (1.0-21.0)
Weight (kg)  26 (8-59) 28 (8-59)  23 (8-57) 
Height (cm) 129 (73-183)  133 (73-183)  122 (74-169) 
BSA (m2) 0.98 (0.39-1.76) 1.03 (0.39-1.76) 0.89 (0.41-1.65) 
BMI (kg/m2) 16.2 (12.4-23.5) 16.6 (12.4-21.8)  15.7 (12.9-23.5) 
 
Disorders
 HUS 26 17 9
 other disorders 76 49 27
 unknown 52 34 18
Center
 Nijmegen 99  65 34 
 Rotterdam 55 35 20
Inulin dose (mg)  2906 (1213-5074) 3031 (1213-5074) 2723 (1239-4769) 
GFR2 (mL/min/1.73m2) 44.5 (2.9-138.8) 46.0 (5.5-138.8)  37.0 (2.9-102.0) 
1Data are presented as median (range)
2GFR was calculated from serum creatinine and height according to Counahan et al (4). 
BSA: body surface area; BMI: body mass index; HUS: hemolytic uremic syndrome
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Study design
All patients had a single cannula into an antecubital vein. They received a single 
intravenous dose (5000 mg per 1.73 m2 body surface area with a maximum of 
5000 mg) of inulin (polyfructosan-S (Inutest®), Laevosan Gesellschaft, Linz, Austria) 
within one minute. Polyfructosan-S is an inulinlike polysaccharide. Serial blood 
samples (1 mL) were collected at 0, 10, 20, 30, 45, 65, 90, 120, 150, 180, 210 and 240 
minutes after injection [5] to construct a concentration-time curve accurately [3]. 
Concentrations of inulin were measured in serum (0.1 mL) by an enzymatic method 
[6]. The coefficient of variation for this method was 0.6% at 481 mg/L and 0.4% at 
995 mg/L [5]. The assay was linear in the range from 0 to 1720 mg/L. 
Population pharmacokinetic analysis
The patients were randomly divided into an index data set (n=100) and a 
validation data set (n=54). Population pharmacokinetic models were developed 
independently for both data sets using the nonlinear mixed-effect modeling 
program NONMEM (double precision; version V, level 1.1, GloboMax LLC). External 
validation of the index set population model was performed by comparison of its 
pharmacokinetic parameters with those of the validation data set. The validation 
procedure and the 2:1 ratio of the index and validation data set are proposed in the 
FDA guideline on population pharmacokinetics [7].
Several pharmacokinetic models (eg. one-, two-, three-compartment models) were 
evaluated for description of the concentration time profiles of inulin. The first-order 
conditional estimation method was used throughout the analyses taking into account 
interaction between inter- and intra-individual variability. Pharmacokinetic parameters 
of the models were estimated in terms of clearance, central and peripheral volume of 
distribution and intercompartmental clearance (NONMEM code TRANS4). For instance, 
for a two-compartmental model the estimated parameters were clearance (CL), volume 
of distribution of the central compartment (V1), intercompartmental clearance (Q) and 
volume of distribution of the peripheral compartment (V2). 
A proportional error model was used to describe the inter-individual variability.  
For instance, the variability in clearance was estimated using:
in which CLi represents the CL of the i
th individual, CLpop is the typical value in the 
population and η is the inter-individual random variable with a mean of 0 and a 
variance of ω2. 
CLi = CLpop x (1+ ηi )
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The residual intra-individual variability 
was modeled with a combined additive-
proportional error model:
where Cobsij is the j
th observed concentration 
in the ith patient, Cpredij is the predicted 
concentration, and ε1 and ε2 are independent 
random variables with a mean of 0 and a 
variance of σ1
2 and σ2
2 . The factors ε1 and 
ε2 account for the difference between the 
observed and predicted concentration. 
The population model was built step by 
step. At each step, a specific assumption was 
tested (e.g. one-compartment versus two-
compartment model or correlation between 
clearance and body surface area). The main 
criterion of decision was the likelihood 
ratio test [8]. For hierarchical models the 
difference between their respective objective 
function values is approximately chi-squared 
distributed and, as a result, formal testing can 
be performed. The level of significance was 
set at p<0.01, corresponding to a difference 
of the objective function values of 6.6 points. 
The objective function value, which equals 
minus twice the logarithm of the likelihood 
of data, is a goodness-of-fit criterion provided 
by NONMEM and has no units. Secondary 
criteria were aspects of the various residual 
plots (“goodness-of-fit” plots) and the 
values of random-effects variances. Possible 
correlation between the demographic 
or pathophysiological indices and the 
pharmacokinetic parameters were explored by 
a three-step approach [9, 10].  
In step 1, an initial NONMEM analysis provided 
the population pharmacokinetic parameters 
without taking into account the demographic 
factors. In step 2 the Bayesian parameter 
estimates of the individual subjects were 
plotted against the demographic factors of 
interest. From the scatter plots, demographic 
factors were selected that correlate with the 
pharmacokinetic parameters. In step 3, the 
NONMEM analysis was resumed, and the 
demographic factors selected in step 2 were 
entered into the NONMEM regression model 
in a stepwise manner to test if a significant 
correlation was present between the 
covariate and the pharmacokinetic parameter. 
Relationships between pharmacokinetic 
parameters and the following covariates were 
tested: AGE (years), body surface area (BSA, 
m2), body weight (WT, kg), height (HT, cm), 
body mass index (BMI, kg/m2), hemolytic 
uremic syndrome / other disorders (HUS / OD), 
center (CENTR, Rotterdam / Nijmegen) and 
SEX (male / female).
The covariates were introduced in the 
population pharmacokinetic model using linear 
relationships. For instance, the relationship 
between CL and BSA was modeled using: 
where θ1 is the typical clearance of a patient 
with a body surface area of 1.1 m2 and θ2 is 
the increment of CL per m2 BSA. Dichotomous 
variables were modeled as follows: 
where HUS is 0 or 1 (absence/presence of HUS), 
CL = θ1 + θ2  x (BSA - 1.1)
CL = θ1 x θ2 
HUS
Cobsij = ε1,ij+ Cpredij  x (1+ε2,ij )
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θ1 is the typical clearance of patients with other disorders and θ2 is the fractional 
increase of CL in case of HUS. 
The final population model was considered adequate when several criteria were 
met: (1) adequate fit of each individual concentration-time curve, (2) linear pattern 
of observed versus predicted inulin concentrations, (3) absence of trend in the 
weighted residuals versus time plot and (4) an approximately normal distribution 
of the weighted residuals. The graphical plots were created in Xpose 2.0, a S-Plus 
based model building aid (Mathsoft Inc, Seattle, USA) [11, 12].
Development of optimal sampling strategies
The population pharmacokinetic model based on the index data set was used for 
the development of the optimal sampling strategies whereas the validation data 
set (n=54) was used for validation of these strategies. Based on the population 
pharmacokinetic parameters derived from the index set optimal sampling times 
were selected by application of the D-optimality theory [13] as implemented in 
the software package Adapt II (release 4, 1997) [14]. The D-optimality theory 
minimizes the total overall variance of parameter estimates based on the Fisher 
information index. 
The optimal sampling strategies were designed with 1 to 4 samples and a total 
sampling time of 90 to 240 minutes. 
Validation of sampling strategies
Plasma concentration time data of the validation set were used to evaluate the 
optimal sampling strategies. Individual Bayesian estimates of clearance were 
calculated using the final population estimates of the index data set and the plasma 
concentrations at the optimal sampling times. The basis of Bayesian estimation 
is that for estimation of the individual pharmacokinetic parameters information 
from the population pharmacokinetic parameters is combined with information 
derived from the actual individual concentrations of the samples [15]. A weighted 
combination of individual and population information where the weighting 
depends on how much information the individual itself supplies, is applied. If a 
large number of accurate blood samples are available the Bayesian estimation will 
largely be determined by the concentration of those samples alone. If, in contrast, 
only 1 blood sample is available the Bayesian estimation will largely be determined 
by the information obtained from the population pharmacokinetic parameters. 
Bayesian analysis was performed using the POSTHOC option in NONMEM with 
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MAXEVAL=0. The Individual reference value 
for clearance (reference inulin clearance) was 
obtained by fitting of the individual curves 
based on all blood samples using extended 
least squares estimation in NONMEM [16].
The predictive performance of the Bayesian 
estimates using the various sampling 
strategies was evaluated by calculating the 
mean relative prediction error (MPE%) and its 
95% confidence interval as a measure of bias 
and the root mean squared relative prediction 
error (RMSE%) and its 95% confidence interval 
as a measure of imprecision [17]. MPE%, 
RMSE% and the standard error for MPE% were 
defined as follows:
in which n is the number of clearance pairs 
(i.e., reference and predicted values) and pe 
is the relative prediction error (ln CL pred 
- ln CL ref ). The relative prediction error 
was calculated with the natural logarithm 
of clearance to avoid bias in favour of 
high clearance values. Ninety five percent 
confidence interval of RMSE% were obtained 
by calculating 95% confidence interval of 
mean squared relative prediction error and 
extracting the root.
RESULTS
Population pharmacokinetic analysis
The full data set consisted of 1675 samples 
collected from 154 pediatric patients. Figure 1 
shows all individual plasma concentration-
time profiles of inulin. Patient characteristics  
of the index and validation set are summarized 
in Table I. Patients in the validation set were 
slightly younger and had a somewhat lower 
GFR. 
Several compartmental models were 
evaluated for description of the inulin 
concentration-time profiles. The analysis was 
started with a one-compartment model with 
inter-individual variability estimated for both 
clearance and the volume of distribution. In 
this model a clear trend was visible in the plot 
of weighted residuals (WRES) versus time. 
This trend disappeared upon introduction 
of a peripheral compartment; the objective 
function decreased with 1388.0 points to a 
value of 10299.8 points (p<0.001). Fitting of a 
three-compartment model did not converge 
satisfactorily. With a two-compartment model 
interindividual variability could be estimated 
for all pharmacokinetic parameters. Estimates 
are given in Table II. 
Individual empirical Bayesian estimates 
of the pharmacokinetic parameters were 
obtained from the basic model with no 
covariates included. Visual inspection of 
the plots of the covariates versus individual 
estimates of parameters indicated correlations 
between BSA, WT, HT and CL, V1, Q and V2. 
For the categorical covariates the following 
MPE% =              x 100%
Σ pei
n
i=1
n
SE% =                           x 100%
Σ (pei - MPE)2
n
i=1
n x (n - 1)
RMSE% =                 x 100%
Σ (pei )2
n
i=1
n
CHAPTER 2 Optimal sampling strategies to assess inulin clearence in childeren by the inulin single injection method
see pages 60 - 63 for references
48
correlations were observed: CL and HUS and CENTR, V1 and CENTR and V2 and 
CENTR. BSA, WT and HT were highly correlated (R2 > 0.9). Since inulin clearance is 
commonly normalized for an average BSA of 1.73 m2 (units of GFR: mL/min/1.73 m2), 
BSA was selected as measure for body size in the population model. Stepwise 
introduction of relationships between all pharmacokinetic parameters and BSA 
in the population model reduced the objective function significantly with 158.9 
(CL; p<0.001), 130.6 (V1; p<0.001), 77.5 (Q; p<0.001) and 201.1 points (V2; p<0.001) 
to a value of 9379.3 points (the objective function value of the basic model was 
9947.4 points). Similar introduction of WT in the basic model produced an objective 
function of 9364.3 points. Despite the 15 points difference in favour of the weight-
pharmacokinetic parameter relationships it was decided to continue with BSA. By 
introduction of the relationship between CL and BSA, the additive error converged 
to 0 and was omitted in the subsequent analyses. This indicated that the (residual) 
difference between observed and predicted concentrations could be described 
adequately with only a proportional error. Implementation of a relationship between 
HUS and CL resulted in the final population model (Table II). Implementation of 
CENTR in the population model did not produce significant reductions of the 
objective function.
Table III shows the regression equations for the pharmacokinetic parameters for 
the final model. The equations between BSA and the pharmacokinetic parameters 
Figure 1
Individual plasma concentration-time profiles of inulin in pediatric patients (n=154) 
after administration of Inutest® (5000 mg per 1.73 m2 BSA) within one minute. 
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Table II. Estimates of the population pharmacokinetic parameters 
  Index data set Index data set Validation data set
  Basic model with  Final model Final model  
  two-compartments 
  
CL (mL/min) 30.6 (3.0)1 25.3 (1.9) 27.8 (2.6)
 θ BSA (mL/min/m2)  32.9 (3.9) 31.4 (4.3)
 θ HUS   2.46 (0.30) 2.67 (0.29)
V1 (L) 1.79 (0.17) 2.07 (0.15) 2.39 (0.36)
 θ BSA (L/m2)  1.70 (0.38) 2.77 (0.67)
Q (mL/min) 90.0 (5.5) 105 (4.0) 93.8 (8.0)
 θ BSA (mL/min/m2)  104 (10) 85.4 (11.2)
V2 (L) 3.15 (0.32) 3.58 (0.17) 3.45 (0.18)
 θ BSA (L/m2)  3.90 (0.33) 3.12 (0.32)
Interindividual variability2
CL (%) 150 56 64
V1 (%) 73 56 50
Q (%) 42 21 18
V2 (%) 47 29 27
Residual variability
Additional error (mg/L)3 20.9 (3.8) - -
Proportional error (%)4 5.69 (1.33) 7.46 (0.64) 7.94 (0.84)
1data are presented as estimate (standard error) 2coefficient of variation in population 3expressed as absolute inulin 
concentration 4expressed as percentage of inulin concentration
BSA: body surface area; HUS: hemolytic uremic syndrome
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were rewritten in order to investigate whether the (intercompartmental) clearance 
(CL, Q) and volumes of distribution (V1, V2) could be expressed in units of mL/min/m
2 
BSA and L/m2 BSA, respectively. For instance, the relationship between CL and BSA 
was rewritten as follows: CL= intercept + slope x BSA. Fitting of this model to the 
data produced a goodness of fit comparable to the final model. Subsequently, 
the intercept was fixated to 0, thereby expressing clearance as CL per m2 BSA and 
reducing the number of estimated parameters (only the slope is estimated). For 
all parameters population models were obtained which were significantly worse 
(p<0.001) than the models with intercepts included. 
Inclusion of the covariate relationships reduced the unexplained inter-individual 
variability in CL, V1, Q and V2. For instance, variability in clearance was decreased from 
150 to 56%: introduction of the covariates BSA and HUS explained 94% of the variability 
in CL. The goodness of fit of the final model is illustrated by plots of population and 
individual predicted concentration values versus observed inulin concentrations in the 
index set (Figure 2). The population predicted inulin concentrations are predicted from 
the population model without taking into account interpatient and residual variability 
(i.e. η=0 and ε=0). Individual predicted inulin concentrations are predicted by Bayesian 
estimation; for each patient individual η values are estimated based on individual 
concentrations. In the plot of population predicted versus observed concentrations  
a slight bias was present at high concentrations, especially at sampling time  
10 min; the population model underpredicted the observations. Underprediction  
of observation could not be associated with weight, height, BSA or BMI of the  
patient; a pre-analytical error was plausible. The bias was absent in the plot of 
individually predicted versus observed concentrations, indicating an adequate fit 
of each individual concentration-time curve. For each individual in the index set 
pharmacokinetic parameters were estimated by Bayesian analysis. Median (and 
Table III. Regression equations describing the relationship between 
the pharmacokinetic parameters  and the covariates for the final 
model (index data set)
CL (mL/min) = (25.3 + 32.9 x (BSA - 1.1)) x 2.46 HUS
V1 (L)  = 2.07 + 1.70 x (BSA -1.1)
Q (mL/min) = 105 + 104 x (BSA -1.1)
V2 (L) = 3.58 + 3.90 x (BSA -1.1)
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Figure 2
Population (PRED) and individual (IPRED) predicted versus observed inulin concentrations for the 
final population model of the index data set. Population predicted inulin concentration is based 
on the pharmacokinetic model without taking into account interpatient and residual variability 
(i.e. η=0 and ε=0). The individual predicted inulin concentration is predicted by Bayesian 
estimation. The solid line represents the line of unity.
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range) of the individual estimates of CL, V1, Q, V2, distribution and elimination half-life 
were: 28 [2-123] mL/min, 1.93 [0.36-6.15] L, 94 [32-195] mL/min, 2.59 [0.84-8.71] L,  
7.9 [3.6-12.3] min and 143 [30-918] min, respectively (n=100). 
The developed population model was validated using the validation data set. No 
bias was observed when the predicted inulin concentrations based on the index 
population model were plotted against the observed concentrations (plot not 
shown). Independent development of a population model based on the validation 
Table IV. Predictive performance of the inulin clearance for 
the sampling strategies in the validation data set
Strategy  Number  Sampling times Bias  Imprecision
 of samples (min) MPE% 95% CI RMSE% 95% CI
1 4 10 / 30 / 90 / 240 1.8 [-1.1, 4.7] 10.7 [6.3, 13.8]
2 4 10 / 30 / 65 / 120 6.7 [-2.7, 16.1] 34.9 [0, 49.4]
3 3 10 / 30 / 90 0.5 [-18.4, 19.5] 68.9 [50.1, 83.6]
4 3 10 / 30 / 240 1.7 [-2.0, 5.6] 14.1 [4.8, 19.3]
5 3 10 / 90 / 240 2.6 [-0.5, 5.7] 11.7 [6.9, 15.0]
6 3 30 / 90 / 240 0.3 [-3.1, 3.7] 12.5 [8.8, 15.2]
7 2 10 / 240 1.7 [-2.5, 6.0] 15.7 [9.4, 20.1]
8 2 30 / 240 -0.1 [-4.7, 4.4] 16.4 [9.6, 21.2]
9 2 90 / 240 1.3 [-2.2, 4.8] 12.8 [9.1, 15.7]
10 1 240 1.0 [-4.0, 5.9] 18.2 [12.1, 22.7]
11 1 210 3.9 [-1.2, 9.0] 19.0 [12.3, 23.8]
12 1 180 3.3 [-5.9, 12.5] 33.6 [0, 49.8]
13 1 150 3.2 [-6.9, 13.3] 37.0 [0, 52.9]
14 1 120 6.8 [-4.0, 17.7] 40.1 [0, 57.1]
MPE: mean relative prediction error
RMSE: root mean squared relative prediction error
CI: confidence interval
53 CHAPTER 2 Optimal sampling strategies to assess inulin clearence in childeren by the inulin single injection method
see pages 60 - 63 for references
data set produced pharmacokinetic parameter 
estimates comparable to the index data set 
(Table II). Separate deletion of the 5 covariate-
pharmacokinetic relationships from the model 
(CL vs BSA and HUS, V1, Q and V2 vs BSA) 
increased the objective function significantly 
(p<0.001). No other significant relationships 
were detected.
Development of optimal sampling 
strategies
For a typical patient with a body surface area 
of 1.1 m2 the following four optimal sampling 
times were found in the observation period 
from 10 to 240 minutes: 10, 25, 79 and 240 min. 
Optimal sampling times were only marginally 
influenced by BSA and presence/absence of 
HUS. Samples close to the optimal sampling 
times were selected from the profiles in the 
validation set. Differences between theoretical 
and actual sampling times were within 15 
minutes. The tested sampling strategies are 
summarized in Table IV.
Validation of sampling strategies
Individual reference values for the clearance 
and other pharmacokinetic parameters were 
calculated using the full plasma concentration-
time profiles. Bias and imprecision of predicted 
clearance for the different sampling strategies 
are given in Table IV. None of the sampling 
strategies was significantly biased. Imprecision 
ranged from 10.7% to 68.9%. The sampling 
strategies 1 (10 / 30 / 90 / 240 min), 4 (10 / 30 / 
240 min), 5 (10 / 90 / 240 min), 6 (30 / 90 / 240 
min) and 9 (90 / 240 min) had a good predictive 
performance with a bias less than 3%, and an 
imprecision not exceeding 15%. 
For example, Figure 3 shows a Bland-Altman 
plot of the Bayesian predicted clearance and 
the reference clearance for sampling strategy 1 
(10 / 30 / 90 / 240 min) and 2 (10 / 30 / 65 / 120 
min).  Typically, in sampling strategy 2 a bias 
was present at low levels of inulin clearance; 
the predicted clearance was larger than the 
reference clearance. This can be explained 
by the fact that the elimination half-life is 
underestimated. This phenomenon was further 
investigated by stratification of predictive 
performance for an individual CL < 40 mL/
min/1.73m2 versus individual CL > 40 mL/min/
1.73m2. For CL > 40 mL/min/1.73m2 no bias was 
observed and the imprecision was smaller than 
15% for the sampling strategies 1 and 4-11. 
For CL < 40 mL/min/1.73m2 the clearance was 
slightly (but not significantly) overestimated 
with bias ranging from 2.8 – 4.8% for the 
sampling strategies 1 and 4-10. Imprecision 
was smaller than 15%. Strategy 1, for example, 
produced a bias of 2.8% (95% CI -0.5, 6.1%) and 
an imprecision of 9.8% (95% CI 0, 13.9%). 
In Figure 4 Bland-Altman plots of the inulin 
clearance are shown for the sampling 
strategies 9 (90 / 240 min) and 10 (240 min). 
The mean difference of the predicted and 
the reference inulin clearance is –0.8 and –1.2 
for strategy 9 and 10, respectively. For both 
sampling strategies a difference of more than 
10 mL/min/1.73m2 was found for only one 
patient. The difference between the predicted 
inulin clearance and the reference clearance 
showed a larger variation at higher GFR. 
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Figure 3
Bland-Altman plots of the predicted and reference inulin clearance in the validation 
data set for sampling strategy 1 (10 / 30 / 90 / 240 min) and 2 (10 / 30 / 65 / 120 min) 
(     mean difference,      2s limits).
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Figure 4
Bland-Altman plots of the predicted and reference inulin clearance in the validation data set for 
the sampling strategies 9 (90 / 240 min) and 10 (240 min) (     mean difference,      2s limits).
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DISCUSSION
For assessing renal function and the rate of progression of renal diseases, reliable 
measurement of GFR is necessary. The reference method (‘gold standard’) to assess 
GFR in children (in a research setting) is the determination of renal clearance 
of inulin during a continuous intravenous infusion. However, this method is 
complex, invasive and time consuming. Alternatively, the plasma clearance of 
inulin can be assessed by a single injection of inulin, which is less complex. After 
administration of a single dose of inulin, serial blood samples are withdrawn to 
construct a plasma concentration-time profile. The plasma clearance of inulin can 
be calculated by dividing the dose by the area under the plasma concentration-
time curve. For practical and convenient application in children it is important that 
the total number of blood samples is minimized. The present study focused on the 
development of an optimal sampling strategy for the inulin single injection method 
in pediatric patients. It was investigated whether inulin clearance could  
be estimated accurately with a reduced number of blood samples. 
A population pharmacokinetic model of inulin was developed based on the plasma 
concentration-time profiles of 100 pediatric patients in the index data set. During 
nonlinear mixed effect modeling the pharmacokinetic model was fitted to the 
data of all patients simultaneously. Typical pharmacokinetic parameters and their 
corresponding interindividual variability were estimated. 
Inulin data were adequately described by a two-compartment model with first-
order elimination from the central compartment. In literature both two- and three-
compartment models have been used to describe the disposition of inulin [3, 18]. 
In the NONMEM analysis addition of a second peripheral compartment did not 
improve the fit of model to the data. This can be explained by the fact that the total 
sampling time in the present study was limited to 240 min. Odeh et al. described 
the pharmacokinetics of inulin based on a 3-compartment model. However, in that 
study samples were collected until 480 min after injection [18]. 
The covariates BSA and HUS correlated significantly with the inulin clearance and 
were included in the final model. They reduced the inter-individual variability from 
150 to 56% and therefore explained 94% of the variability between the subjects. 
BSA was found as a significant covariate, which is to be expected since GFR varies 
with body size. For children GFR is usually expressed per 1.73m2 BSA (i.e. mL/min/
1.73m2) for standardization and comparison between individuals of different sizes. 
Patients with HUS had on average a higher clearance compared with patients with 
other disorders (factor 2.46). This may be explained by the fact that the patients 
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with HUS in our data set were totally or partly 
recovered from HUS and had a (nearly) normal 
renal function (all patients with HUS in the 
validation set had a inulin clearance >100 
mL/min/1.73m2). Kinowski et al. found also 
BSA as a significant covariate for clearance and 
volume of distribution of inulin in adults with 
diabetes or obesity [19].
The population pharmacokinetic model 
described the data adequately (Figure 2) and 
showed a low residual variability (proportional 
error of 7.5%). The validity of the population 
model was demonstrated by performing an 
identical analysis with the validation data 
set, yielding comparable results for mean 
pharmacokinetic parameters, variance and 
relationships with covariates. 
Since 11 blood samples were available for 
each patient the Standard Two Stage method 
may also be used to produce population 
parameter estimates. Although application 
of this method usually produces unbiased 
mean estimates of parameters, random effects 
(variance and covariance) are likely to be 
overestimated in all realistic situations [20].
D-optimality theory was used for the selection 
of optimal sampling times. From the optimal 
sampling times different sampling strategies 
with one to four sampling times were 
developed and tested for the validation data 
set using Bayesian estimation. With Bayesian 
estimation the individual pharmacokinetic 
parameters are estimated using the 
derived population model and the plasma 
concentrations at the selected sampling times. 
Application of Bayesian analysis provides the 
advantage of estimating a pharmacokinetic 
parameter using only a few sampling times. 
Furthermore, there is no need for the sampling 
times to be exact. This is an advantage 
over other methods like multivariate linear 
regression techniques, which requires that 
the actual sample is taken at the specified, 
optimal sampling time [21, 22]. The Bayesian 
estimation method is implemented in several 
commercially available pharmacokinetic 
programs (for example NONMEM, PKS, USC-
PACK, P-PHARM and MW/Pharm). 
For all of the tested sampling strategies, it was 
found that the inulin clearance was assessed 
well by Bayesian estimation when at least a 
sample at 240 min was included. Limiting the 
total sampling time window from 0-240 to 
0-120 min (strategy 2) resulted in a reduction 
of the predictive performance, indicating 
that the sampling time of 240 minutes after 
injection is critical for adequate estimation 
of the inulin clearance. One study in children 
and adults described that a total sampling 
time of 180 min was sufficient to estimate the 
inulin clearance [23]. However, in that study 
the predictive performance of the strategy 
was not tested and only a minority of patients 
presented a CL < 40 ml/min/1.73m2. In our 
study the predictive performance of the 
sampling strategy with even one sample  
at 240 min (strategy 10) was acceptable for 
CL < 40 ml/min/1.73m2 (bias 4.8 % (95% CI: -0.1 
to 9.6), imprecision 14.6 % (95% CI: 0 to 20.6)).
The sampling strategies 1 (10 / 30 / 90 / 240 min), 
4 (10 / 30 / 240 min), 5 (10 / 90 / 240 min),  
6 (30 / 90 / 240 min), and 9 (90 / 240 min) 
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produced accurate predictions of inulin clearance with a bias not significantly 
different from zero and an imprecision not exceeding 15%. The predictive 
performance of strategy 10 with only 1 sample taken at 240 min was acceptable 
as well (bias 1.0 % (95% CI: -4.0 to 5.9) and an imprecision 18.2 % (95% CI: 12.1 to 
22.7)). These results are in accordance with a previously reported study on the 
development of a limited sampling model using Bayesian estimation in adults with 
diabetes or obesity, showing that with one or two samples the inulin clearance 
was well estimated [19]. Swinkels et al. reduced the total number of required blood 
samples from 11 to 6 for the determination of the inulin clearance in children 
[5]. Four samples were used to describe the distribution phase and 2 samples 
to describe the elimination phase. Since a model built in the program SAS was 
used for non-linear fitting it was not possible to reduce the required number 
of blood samples to less than 4. This applies also for the results of Florijn et al. 
(SIPHAR program) and Orlando et al. (GraphPad Prism) in adults [2,3]. However, 
with Bayesian estimation, which combines population information and individual 
information, it is possible to reduce the total number of required blood samples 
to as low as 1 [15]. In addition no optimal sampling strategies were developed 
in the study of Swinkels et al. and the model was not validated. Several other 
authors described the simplification of the inulin single injection method for the 
determination of the GFR in adults by using the slope clearance method instead of 
Bayesian estimation [24-29]. The slope clearance method is based on calculation of 
the AUC by the slope (rate constant) and the extrapolated inulin concentration at 
0 minutes (Y- intercept). However, in nearly all those studies no optimal sampling 
times were determined and the simplified method was not validated.
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In conclusion, the sampling strategies of two 
to four sampling times and a total sampling 
time of 240 min result in a good prediction 
of inulin clearance in children with a non 
significant bias and a good imprecision  
(< 15%). The sampling strategy with two 
samples (90 and 240 min) seems very practical 
but one relies heavily on impeccable pre-
analytical procedure and assay of both 
samples with no room for errors. Four 
sampling times (10 / 30 / 90 / 240 min) provide 
additional accuracy. Even the sampling 
strategy with 1 blood sample at 240 min 
could be used in certain cases. With the 
development of optimal sampling strategies 
for the inulin single injection method the 
burden of repetitive blood sampling from 
children to assess the GFR by the inulin 
single injection method can be reduced 
considerably. As a result, the determination of 
GFR based on the approach presented in this 
paper becomes more practical and offers more 
patient convenience, without compromising 
accuracy.
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and 240 minutes after administration. For the 
continuous infusion method inulin was started 
overnight and blood samples were collected 
the next day.  
The inulin plasma clearance determined by 
the single injection method was on average 
9.7 mL/min/1.73m2 higher than the clearance 
determined with the continuous infusion 
method (95% CI: 5.3; 14.2). The difference 
between both methods was smaller at lower 
GFRs. 
The difference in results generated by the two 
methods in children is small and is considered 
acceptable in clinical practice. For practical 
reasons, the single injection method with 
minimum sampling is preferred. 
ABSTRACT
The reference method to determine 
the glomerular filtration rate (GFR) in 
children is the urinary clearance of inulin 
during a continuous intravenous infusion. 
Alternatively, the plasma clearance of 
inulin can be determined, which does not 
require urine collection. The aim of this 
study was to compare the inulin plasma 
clearance in pediatric patients determined 
by two methods: the single injection and the 
continuous infusion method.
The inulin plasma clearance was determined 
in 24 patients by both methods. In the single 
injection method 5000 mg/m2 of inulin 
(Inutest®)was administered as bolus injection 
and blood samples were drawn at 10, 30, 90 
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INTRODUCTION
Glomerular Filtration Rate (GFR) is considered the most fundamental parameter 
in the evaluation of renal function in suspected renal diseases and in monitoring 
renal function during treatment. The ideal marker for GFR determination would 
be physiologically inert, freely filtered in the glomerulus, neither secreted nor 
reabsorbed by the renal tubule, and not synthesized or metabolized by the kidney. 
Inulin, an exogenous polysaccharide, has all of these properties. Consequently, 
the urinary clearance of inulin during continuous intravenous infusion of inulin is 
regarded as the gold standard for determining GFR in children [1]. However, this 
method requires an intravenous infusion of inulin and timed urine collections 
over a period of several hours, which is difficult and needs bladder catheterization, 
especially in smaller children. As a result, alternative methods, without collection of 
urine, have been developed.
The plasma clearance of inulin can be measured after either a continuous 
intravenous infusion or a single bolus injection. The continuous infusion method 
is based on the concept that when the plasma concentration of the marker is 
constant (steady state concentration) and the volume of distribution is saturated 
with the marker (state of equilibrium), the rate of excretion equals the rate of 
infusion [1, 2]. The time to reach a steady state concentration is critical, since 
GFR is overestimated if a steady state concentration has not been reached. An 
equilibration period of one to three hours is common but there are data indicating 
that a period of more than 12 hours may be required for a complete equilibrium of 
inulin in the extracellular volume [3, 4, 5]. In general the steady state concentration 
of a drug (90% of the steady state) is reached in 3.3 half-lives [6]. Therefore in 
the case of decreased renal function the time to achieve steady state is delayed. 
However, a loading dose can be given to reach the steady state concentration  
more rapidly. 
In the Sophia Children’s Hospital, the inulin plasma clearance with continuous 
infusion has been used as the standard method to determine GFR for many years. 
With this method, hospitalization is necessary for the duration of the inulin infusion 
and while three capillary blood samples are drawn. This makes it both time-
consuming and inconvenient.
The single injection method can be performed in daycare, with only one venous 
puncture for the administration of inulin and for the collection of blood samples. A 
bolus of inulin is administered intravenously and blood samples are collected up to 
240 min after injection. The inulin concentrations measured are used to construct 
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a plasma concentration vs time decay curve 
[1]. For an accurate description of the curve 
10-12 blood samples are usually required. It 
is stressful for children to draw a lot of blood 
samples and therefore limited and optimal 
sampling strategies were introduced [7, 8]. As 
a result the inulin single injection method is 
more convenient for patients and nurses.
In adults good agreement has been reported 
between the plasma clearance of inulin 
determined by the single injection method 
and the continuous infusion method [9, 10]. 
No similar comparison has been made in 
children.   
The aim of this study was to compare the 
plasma clearance of inulin determined by the 
single injection method and the continuous 
infusion method in pediatric patients.
METHODS
Patients
The study was approved by the Medical Ethics 
Committee of the hospital and informed 
consent was obtained from patients or their 
parents. Twenty-four pediatric patients with 
stable renal function were included between 
March 2000 and November 2002. All the 
patients were hospitalized at the Sophia 
Children’s Hospital of Rotterdam for various 
reasons. Patient characteristics are summarized 
in Table I. Two patients were included twice: 
one patient showed a decrease in GFR (from 
20 to 12 mL/min/1.73m2) and the other patient 
received a renal transplant and had GFRs of 
14 and 95 mL/min/1.73m2, before and after 
transplantation, respectively.
Study design
In all patients a single cannula was inserted 
into an antecubital vein. The single injection 
method started in the morning at 9.00 h. 
From midnight before the diet was restricted: 
no fruit, lemonade, or caffeinated beverages 
were allowed. Inulin (polyfructosan, Inutest®, 
Fresenius Pharma, Graz, Austria) was infused 
in a dose of 5000 mg/1.73 m2 body surface 
area (maximum dose 5000 mg), at a constant 
rate over 30 seconds. The precise dose was 
determined by weighing the syringe before 
and after injection on a highly accurate 
balance. After administration of inulin the 
cannula was flushed with 20 ml of 0.9% saline. 
Blood samples (heparin samples) of 1 ml were 
taken at 0, 10, 30, 90 and 240 minutes after 
injection. Between sampling the cannula was 
kept open with a heparin lock. To prevent 
dilution of a blood sample with heparin 
the first 2.5 mL of blood was drawn prior to 
sampling and, if possible, re-injected after 
sampling.  
At the end of the single injection method the 
continuous infusion method was started. The 
infusion rate was calculated as follows [9]:
 
in which R is the infusion rate of inulin 25% 
solution (mL/h), BH is the body height (cm), 
BSA is body surface area (m2) and Pcr is the 
plasma concentration of creatinine (μmol/L). 
R =     
2 x BH x BSA
Pcr
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Table I. Patient characteristics1
Patients 24
 male / female 11 / 13
Age (years) 10.3 (2.4 - 17.9)
Weight (kg) 24 (13 – 48)
Height (cm) 128 (88 – 165)
BSA (m2) 0.93 (0.55 – 1.50)
BMI (kg/m2) 16 (13 – 20)
Disorders
 renal transplantation 9
 chronic renal failure 5
 acute renal failure 1
 other renal disorders 4
 heart transplantation 1
 urological disorders 1
 other disorders 3
GFR (mL/min/1.73m2)2 42.0 (10.6 – 125.9)
1Data are presented as median (range)
2GFR: plasma clearance of inulin determined by the continuous infusion method 
BSA: body surface area; BMI: body mass index
Table II. Population pharmacokinetic parameters of inulin
  Mean Coefficient of variation (%) 
CL (L/h/1.85m2) 2.02   61 
V1 (L/kgLBMc) 0.0655  57
Q (L/h/1.85m2) 10.7  21
V2 (L/kgLBMc) 0.119  26
CL: plasma clearance of inulin; V1: volume of distribution of the central compartment; Q: 
intercompartmental clearance; V2: volume of distribution of the peripheral compartment; LBMc: lean body 
mass corrected for fat distribution
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During the first two hours the infusion rate 
was doubled to saturate the compartments 
faster. The infusion was continued overnight. 
Capillary samples were taken the next day 
at 11.00, 12.00 and 13.00 h and collected in 
heparin microtainers. 
Biochemical assay
In the laboratory the blood samples were 
centrifuged and serum samples were stored 
at -20 °C.
To determine the inulin concentration, frozen 
samples were thawed completely and 150 μL 
was deproteinized by perchloric acid (1:1). 
Samples were then centrifuged for 10 min 
at 10.000 rpm (9500 g). The supernatant was 
neutralized with 5 M KOH, and centrifuged 
for another 10 min. Thereafter, concentrations 
of inulin were measured in the supernatant 
(0.1 mL) in duplicate by an automated 
enzymatic method [11, 12]. Inulinase 
hydrolyses inulin to fructose and sorbitol 
dehydrogenase converts fructose to sorbitol 
with the consumption of NADH, which is 
detected spectrofotometrically on a Hitachi 
912 (Roche Diagnostics). The analytical 
coefficient of variation for this method  
was 6.9% at 136 mg/L and 1.9% at 725 mg/L.  
The assay was linear up to 2100 mg/L. 
Pharmacokinetic analysis
For the single injection method the inulin 
plasma clearance was obtained by fitting 
the plasma concentration-time decay curve 
of inulin to a two-compartment model by 
Bayesian analysis using the pharmacokinetic 
software program MW/Pharm version 3.50 
(Mediware, Groningen, the Netherlands).  
The basis of Bayesian analysis is that for 
estimation of the individual pharmacokinetic 
parameters information from the population 
pharmacokinetic parameters is combined with 
information derived from the actual individual 
concentrations of the samples. A weighted 
combination of individual and population 
information where the weighting depends 
on how much information the individual 
itself supplies, is applied. The population 
pharmacokinetic parameters of inulin are 
presented in Table II. If a large number of 
accurate blood samples is available the 
Bayesian estimation will largely be determined 
by the concentration of those samples alone. 
If, in contrast, only 1 blood sample is available 
the Bayesian estimation will largely be 
determined by the information obtained from 
the population pharmacokinetic parameters. 
More information from the population 
pharmacokinetic parameters is added to the 
actual concentrations with decreasing number 
of samples.  
For the continuous infusion method GFR was 
calculated as follows:
 
in which R is the infusion rate (mL/h) and  
Pi the mean plasma concentration of inulin 
from the capillary samples (mg/mL).
GFR was corrected for body surface area  
(mL/min/1.73m2).
GFR (mL/min)=   
R x 250
Pi x 60
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Statistical analysis
Results were presented as median and range. The correlation coefficient (R2) 
was used to describe the strength of the relation between the inulin single 
injection method and the continuous infusion method. Agreement between the 
two methods was evaluated as described by Bland and Altman [13]. The limits 
of agreement represent the range around the mean difference between both 
methods in which 95% of the values will be found (mean difference ± 1.96 x SD). 
The 95% confidence intervals of the mean difference were calculated by the mean 
difference ± t x standard error of the mean difference.
The statistical analysis was made by using the GraphPad Prism version 4.00 for 
Windows (GraphPad Software, San Diego, USA). 
RESULTS
After overnight infusion of inulin a steady state concentration was reached for the 
continuous infusion method in all patients (difference between the samples < 15% 
except in 1 patient). The steady state concentration of inulin varied from 312 to 
1006 mg/L. In 3 patients one of the capillary blood samples was not available due 
to a (pre-) analytical error.  
Table III presents the individual plasma clearance of inulin for the single injection 
method and the continuous infusion method. GFR found by the single injection 
method varied from 13.6 to 150.9 mL/min/1.73m2. The relationship between the 
plasma clearance of inulin determined by the single injection method with 4 blood 
samples (10 / 30 / 90 / 240 min) and the inulin plasma clearance based on the 
continuous infusion method is shown in Figure 1. The coefficient of correlation was 
0.92. The inulin plasma clearance determined by the single injection method was 
higher than the inulin plasma clearance based on the continuous infusion method 
at all levels of GFR, except in 2 patients. The mean inulin plasma clearance for the 
single injection method was 61.6 mL/min/1.73m2, while a mean plasma clearance 
of 51.9 mL/min/1.73m2 was found for the continuous infusion method. The mean 
difference in inulin plasma clearance between the single injection method and the 
continuous infusion method was 9.7 mL/min/1.73m2 (Figure 2).  
The 95% confidence interval for the mean difference was 5.3 - 14.2 mL/min/1.73m2, 
which shows that the mean difference was statistically significant. Limits of 
agreement (mean difference ± 1.96 SD) were - 10.9 and 30.4 mL/min/1.73m2.  
The difference between both methods was smaller at lower GFRs. 
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Table III. Individual plasma clearance of inulin (mL/min/1.73m2) determined 
by the single injection method and the continuous infusion method (n=24)
   Inulin clearance determined by
Patient no. single injection continuous infusion
 (mL/min/1.73m2) (mL/min/1.73m2) 
1 150.9 125.6 
2 38.3 27.7 
3 66.6 54.6  
4  21.7 14.2  
5  27.3 21.0  
6  53.9 39.8  
7  48.8 42.0  
8  34.4 26.9  
9  56.9 41.9  
10  22.3 16.3  
11  123.6 125.9  
12  101.8 124.7  
13  116.4 101.2  
14  18.9 12.9  
15  47.7 47.1   
16  56.6 43.3  
17  48.4 43.4  
18  95.9 83.4  
19  13.6 10.6  
20  55.5 40.1  
21  105.9 80.8  
22  49.8 37.6  
23  99.0 66.6  
24  23.9 16.8  
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Figure 1
Correlation between the plasma clearance of inulin determined by the single 
injection method (GFR-SI) and by the continuous infusion method (GFR-CI) 
(      line of identity; Y = -5.384 + 0.9293 X).
200
150
100
50
0
G
FR
 - 
CI
 (m
L/
m
in
/1
.7
3m
2 )
0 50  100  150  200
GFR - SI (mL/min/1.73m2)
50
25
0
-25
-50
(G
FR
 - 
SI
 ) 
- (
G
FR
 - 
CI
)
 50  100  150  200
(GFR - SI + GFR - CI) / 2
Figure 2
Bland-Altman plot of the inulin plasma clearance determined by the single 
injection method (GFR-SI) and the continuous infusion method (GFR-CI)  
(      mean difference,      limits of agreement).
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For GFRs < 50 mL/min/1.73m2 a mean 
difference of 8.5 mL/min/1.73m2 (95% CI: 6.2; 
10.9; limits of agreement: –0.11; 17.2), while for 
GFRs > 50 mL/min/1.73m2 a mean difference 
of 12.2 mL/min/1.73m2 (95% CI: -3.5; 27.0;  
limits of agreement: –22.6; 46.9) was observed. 
DISCUSSION
The inulin plasma clearance determined by 
the single injection method correlated well 
with the continuous infusion method. The 
single injection method resulted in an inulin 
plasma clearance, that was, on average, 9.7 
mL/min/1.73m2 higher than the clearance 
determined with the continuous infusion 
method. This mean difference was statistically 
significant. The mean difference was smaller 
for GFRs < 50 mL/min/1.73m2, which are the 
GFRs of clinical interest. It is important to 
realize that bias in the continuous infusion 
method could also account for this difference. 
Theoretically it is even possible that the 
single injection method is a more accurate 
representation of the urinary clearance of 
inulin than the continuous infusion method. 
Unfortunately, the trial was not designed to 
investigate this point.
The findings are in accordance with the results 
of Florijn et al., who compared the plasma 
clearance of inulin determined by the single 
injection method with the continuous infusion 
method in 14 adult patients with autosomal-
dominant polycystic kidney disease with a GFR 
range of 27 - 137 mL/min/1.73m2 [9]. In that 
study a correlation coefficient (r) of 0.95 was 
found and an overestimation was observed 
for the inulin single injection method (mean 
difference between both methods 7 mL/min/
1.73m2). 
The difference in results between the single 
injection and the continuous infusion method 
cannot be explained by the use of venous 
versus capillary blood samples. Müller-Suur 
et al. compared the inulin plasma clearance 
with single injection based on venous and 
capillary blood samples in 21 children [14]. 
Good agreement between the two methods 
was found (r=0.94). Bäcklund et al. studied the 
same relationship in 31 children and adults. 
In that study a correlation coefficient of 0.89 
was observed [15]. We compared the inulin 
concentration in venous and capillary blood 
samples in 13 children (data not shown). In 
general the inulin concentration corresponded 
well between the blood samples (mean 
difference 12 mg/L, not statistically significant). 
A circadian rhythm for GFR has been described 
[16]. Since the blood samples were taken at 
similar times for both methods, it is unlikely 
that this explains the difference.
Determination of the urinary clearance 
of inulin during continuous intravenous 
infusion of inulin is regarded as the gold 
standard to determine GFR in children. Since 
no comparison was made, it is not clear 
which method will agree better with the 
urinary clearance of inulin. Determination 
of the urinary clearance of inulin requires 
an intravenous infusion of inulin and timed 
urine collections over a period of several 
hours, which is difficult and needs bladder 
CHAPTER 3 Determination of inulin clearance by single injection or infusion in children
see page 75 for references
74
catheterization, especially in smaller children. Urine samples are not required to 
determine the plasma clearance of inulin.    
The single injection method has several advantages over the continuous infusion 
method in determining the plasma clearance of inulin. The former method takes  
4 hours while the continuous infusion method generally requires an overnight stay 
since a steady state concentration has to be reached [3]. It is important for patients 
that the total number of blood samples required is minimal. The number of blood 
required was nearly similar in the two methods (4 for the single injection method 
and 3 for the continuous infusion method). However, the continuous infusion 
method required capillary blood samples since it was not possible to draw blood 
from the cannula while the inulin was being infused. 
In conclusion, determination of the inulin plasma clearance in children with the 
single injection method resulted in a small but not clinically relevant overestimation 
of the inulin plasma clearance compared with the continuous infusion method.  
The discrepancy between the results was smaller at GFRs below 50 mL/min/1.73m2.  
The practical advantages (no overnight stay and less cumbersome) make the 
inulin single injection method with minimal blood sampling preferable for the 
determination of the plasma clearance of inulin in children.
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CHAPTER 4
BEPALING VAN DE GLOMERULAIRE FILTRATIESNELHEID 
BIJ KINDEREN DOOR MIDDEL VAN DE INULINE SINGLE 
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with the inulin plasma clearance based on all 
blood samples (reference clearance).  
In patients with GFR < 75 mL/min/1.73m2 the 
mean difference between the inulin plasma 
clearance based on 4 blood samples and 
the reference clearance was not statistically 
significant. For GFR > 75 mL/min/1.73m2 a 
small bias was observed (mean difference: 
-5.92 mL/min/1.73m2; 95% confidence interval: 
-10.2; -1.68 mL/min/1.73m2). 
In patients with decreased renal function the 
inulin plasma clearance determined by the 
single injection method with 4 blood samples 
agreed well with the inulin plasma clearance 
based on 11 blood samples. As a consequence, 
it is a simple and convenient method to 
determine the renal function in pediatric 
patients. 
ABSTRACT 
Renal function can be assessed by 
determination of the glomerular filtration rate 
(GFR). The standard method to determine GFR 
in children is the urinary clearance of inulin 
during a continuous intravenous infusion. 
However, this method is complex and invasive. 
Alternatively, the plasma clearance of inulin 
can be determined by single injection of 
inulin. The aim of this study was to validate the 
single injection method with a limited number 
of blood samples in pediatric patients.
Determination of the inulin plasma clearance 
by single injection was performed in 48 patients. 
A single injection of inulin (Inutest®, 5000 
mg/m2) was administered and blood samples 
were drawn at 0, 10, 20, 30, 45, 60, 90, 120, 
150, 180 and 240 minutes after administration. 
The inulin plasma clearance based on 4 blood 
samples (10, 30, 90 and 240 min) was compared 
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INLEIDING
De glomerulaire filtratiesnelheid (GFR) is de belangrijkste parameter om de 
nierfunctie te volgen bij nierziekte en tijdens behandeling met geneesmiddelen. 
De ideale marker om de nierfunctie te bepalen is fysiologisch inert, wordt 
vrij gefiltreerd in de glomerulus, kent geen tubulaire secretie en wordt niet 
gereabsorbeerd, gesynthetiseerd of gemetaboliseerd in de nieren. Inuline, een 
exogeen polysaccharide, wordt beschouwd als de ‘gouden marker’ omdat het 
alle eigenschappen van een ideale marker heeft [1]. Zowel de urine klaring 
als de plasma klaring van inuline kan worden bepaald. Bij het bepalen van de 
plasma klaring van inuline wordt het verdwijnen van inuline uit het plasma in 
de loop van de tijd gevolgd. Inuline wordt via continue infusie (inuline continue 
infusiemethode) of eenmalige injectie (inuline single injectie methode) toegediend. 
De inuline single injectie methode, waarbij inuline als bolus injectie intraveneus 
wordt toegediend en op een aantal tijdstippen bloedmonsters worden afgenomen 
voor het opstellen van de plasma verdwijningscurve, is in een aantal opzichten 
praktischer. De totale periode voor het bepalen van de inuline plasma klaring kan 
beperkt blijven tot 4 uur en er hoeft slechts eenmaal geprikt te worden voor  
het inbrengen van een afname-canule. Voor het nauwkeurig beschrijven van de 
plasma verdwijningscurve was tot voor kort een groot aantal bloedmonsters nodig 
(10-12). Door het opstellen van gelimiteerde en optimale bemonsteringsschema’s 
voor de inuline single injectie methode is het aantal af te nemen bloedmonsters 
sterk gereduceerd, waardoor de methode patiëntvriendelijker is geworden [2, 3].
In dit artikel wordt de praktische uitvoering van de inuline single injectie methode 
met een beperkt aantal bloedmonsters voor het bepalen van de inuline plasma 
klaring bij kinderen en de validatie ervan beschreven.
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METHODEN
Patiënten
Het onderzoek vond plaats op de afdeling 
Thuisdialyse van het Erasmus MC-Sophia in 
Rotterdam. Tussen april 2000 en augustus 
2002 ondergingen 48 kinderen een test voor 
het bepalen van de inuline plasma klaring. 
Deze test werd ’s ochtends gestart. Inuline 
(polyfructosaan, Inutest®, Fresenius Pharma, 
Graz, Oostenrijk) werd via een canule in een 
antecubitale vene in een dosis van 5000 
mg/1.73 m2 lichaamsoppervlak (maximale 
dosis 5000 mg) met een constante snelheid 
in 30 seconden geïnjecteerd. De precieze 
dosis inuline werd bepaald door de spuit 
voor en na het geven van inuline te wegen. 
Na toediening van inuline werd de canule 
doorgespoeld met 20 ml natriumchloride 
0.9%. Bloedmonsters (1 ml) werden 
afgenomen op de tijdstippen 0, 10, 20, 30, 
45, 60, 90, 120, 150, 180 en 240 min na 
toedienen van inuline [2]. Na het afnemen 
van elk monster werd 1 mL heparine  
(4 IE/mL) toegediend. Om verdunning van 
het af te nemen bloedmonster te voorkomen 
werd de eerste 2.5 mL bloed terzijde gelegd 
en indien mogelijk na het afnemen van het 
bloedmonster teruggegeven. 
Biochemische analyse 
De bloedmonsters werden bij binnenkomst 
gecentrifugeerd en serum of heparine plasma 
monsters werden opgeslagen bij -20 °C. Voor 
het bepalen van de inuline concentratie 
werden de monsters ontdooid en onteiwit 
met perchloorzuur. De inuline concentratie 
werd gemeten met een geautomatiseerde 
enzymatische methode (Hitachi 912,  Roche 
Diagnostics) [4, 5]. De variatiecoëfficiënt 
voor deze methode bedroeg 6.9% bij een 
inuline concentratie van 136 mg/L en 1.9% 
bij 725 mg/L. De methode was lineair tot een 
concentratie van 2100 mg/L. 
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Farmacokinetische analyse
De farmacokinetiek van inuline werd beschreven met behulp van een 2-compartiment 
model. Individuele curves gebaseerd op alle afnametijdstippen werden gefit met 
behulp van een gemodifideerde kleinste kwadraten methode en de individuele 
inuline klaring werd hieruit geschat [6]. In het geval van 4 afnametijdstippen werd 
een schatting van de inuline klaring verkregen door Bayesiaanse analyse zoals 
geïmplementeerd in het farmacokinetiek programma MW/Pharm versie 3.50 
(Mediware, Groningen). MW/Pharm is een farmacokinetiek programma dat in bijna elke 
ziekenhuisapotheek beschikbaar is. Bij Bayesiaanse analyse werden de concentraties 
op de 4 tijdstippen 10, 30, 90 en 240 minuten gecombineerd met de populatie 
farmacokinetische gegevens van inuline (Tabel I). Door combinatie van individuele en 
populatie gegevens kan voor een individuele patiënt met minder afnametijdstippen 
de inuline klaring worden geschat. De afnametijdstippen 10, 30, 90 en 240 minuten na 
toediening zijn afgeleid van een optimaal bemonsteringsschema voor inuline [3].
Tabel I. Populatie farmacokinetische parameters voor inuline
  Gemiddelde Variatiecoëfficiënt (%) 
CL (L/u/1.85m2) 2.02   61 
V1 (L/kgLBMc) 0.0655  57
Q (L/u/1.85m2) 10.7  21
V2 (L/kgLBMc) 0.119  26
Residuale fout: 7.54%
CL: inuline plasma klaring; V1: verdelingsvolume centraal compartiment; Q: intercompartimentele klaring; V2: 
verdelingsvolume perifeer compartiment; LBMc: lean body mass gecorrigeerd voor vetverdeling
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(gemiddeld verschil ± 1.96 x SD). Het 95% 
betrouwbaarheidsinterval van het gemiddelde 
verschil in inuline klaring werd berekend door 
middel van het gemiddelde verschil  
± t x standard error, waarbij t het getal is dat 
hoort bij een verdeling van n-1 vrijheidsgraden.
RESULTATEN
Bij 48 patiënten (Tabel II), in leeftijd  
variërend van 5 tot 18 jaar, werd de inuline 
plasma klaring bepaald. Bij het merendeel 
van de patiënten werd de test als routine 
uitgevoerd om de nierfunctie na transplantatie 
te volgen. Bij 13 patiënten werd de inuline 
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Statistische analyse
De overeenkomst tussen de inuline 
plasma klaring verkregen op grond 
van de 4 afnametijdstippen en alle 11 
afnametijdstippen (referentie inuline klaring) 
werd beschreven aan de hand van een Bland-
Altman grafiek [7]. Het verschil in inuline 
klaring werd uitgezet tegen de gemiddelde 
inuline klaring ((inuline klaring gebaseerd op 4 
afnametijdstippen + referentie inuline klaring) 
/ 2). De limits of agreement in de Bland-
Altman grafiek geven het bereik rondom 
het gemiddelde verschil in inuline klaring 
aan, waarbinnen 95% van alle waarden ligt 
Tabel II. Patiëntkarakteristieken1
Patiënten 48
 mannelijk / vrouwelijk 34 / 14
Leeftijd ( jaren) 13 (5-18)
Gewicht (kg) 47 (20-82)
Lengte (cm) 152 (106-186)
Lichaamsoppervlakte (m2) 1.44 (0.75-1.98)
Kreatinine concentratie (μmol/L) 89 (35-434)
Plasma klaring van inuline (mL/min/1.73m2) 71 (7-158)
Ziektebeeld 
 Niertransplantatie 38 
 Overig 10 
1Data worden weergegeven als mediaan (bereik)
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Figuur 1
Inuline verdwijningscurve uit het plasma (patiënt met BSA: 0.98 m2, dosis Inutest: 
3155 mg). De bovenste curve (     ) geeft de curve aan op grond van de populatie 
farmacokinetische gegevens van inuline (inuline klaring: 31.5 mL/min/1.73m2); de 
onderste curve (     )  is een individuele curve opgesteld met Bayesiaanse analyse, 
waarbij de inuline plasma concentraties op de tijdstippen 10, 30, 90 en 240 minuten  
( O ) gecombineerd zijn met het populatiemodel (inuline klaring: 50.9 mL/min/1.73m2).   
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klaring in de aangegeven periode twee keer bepaald. De inuline plasma klaring 
varieerde van 7 tot 158 mL/min/1.73 m2 (mediaan 71 mL/min/1.73m2). In Figuur 1  
is een voorbeeld van een verdwijningscurve van inuline uit het plasma weergegeven.  
De Bland-Altman grafiek voor de inuline klaring op basis van 4 en 11 afnametijdstippen 
is in Figuur 2 weergegeven. Voor een GFR kleiner dan 75 mL/min/1.73m2 werd een 
gemiddeld verschil van –0.60 mL/min/1.73m2 met een 95% betrouwbaarheidsinterval 
van –1.51 tot 0.35 gevonden (n=29). Een gemiddeld verschil van –5.92 mL/min/
1.73m2 (95% betrouwbaarheidsinterval –10.2; -1.68) werd waargenomen bij een GFR 
groter dan 75 mL/min/1.73m2 (n=19). 
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Figure 2
Bland-Altman grafiek voor de inuline plasma klaring gebaseerd op 4 afnametijdstippen 
(klaring MW/Pharm) en 11 afnametijdstippen (referentieklaring)  voor GFR < 75 mL/min/
1.73m2  (bovenste figuur) en GFR > 75 mL/min/1.73m2 (onderste figuur)
(      gemiddeld verschil,      limits of agreement).
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DISCUSSIE
Voor het meten van de GFR kunnen verschillende markers worden gebruikt. 
De ideale marker om de nierfunctie te bepalen is fysiologisch inert, wordt 
vrij gefiltreerd in de glomerulus, kent geen tubulaire secretie en wordt niet 
gereabsorbeerd, gesynthetiseerd of gemetaboliseerd in de nieren. In het geval 
van een endogene marker is een constante productie snelheid eveneens een 
vereiste. Markers voor de GFR kunnen worden onderverdeeld in exogene en 
endogene markers. Tot de exogene markers behoren inuline, radio-isotopen 
(125I-iothalamaat, 51Cr-EDTA en 99mTc-DTPA) en iohexol. Kreatinine en cystatine C 
zijn endogene markers. Inuline, een polysaccharide, heeft alle eigenschappen 
van een ideale marker en wordt gezien als de ‘gouden standaard’. Het gebruik 
van radio-isotopen als marker voor GFR bij kinderen is in Nederland beperkt 
vanwege veiligheidsaspecten (blootstelling aan straling). Iothalamaat kan ook in 
niet gelabelde vorm worden gebruikt, maar in de literatuur is tubulaire secretie 
van iothalamaat beschreven, waardoor het geen ideale marker voor de GFR is [8]. 
Iohexol is een laag osmolair non-ionogeen contrastmedium (molecuulgewicht 
821 Da). Ervaring met iohexol als marker voor GFR bij kinderen is beperkt. Daarom 
wordt de voorkeur gegeven aan inuline als exogene marker voor het bepalen van 
de GFR bij kinderen. 
De klassieke methode voor het bepalen van de GFR bestaat uit het toedienen 
van inuline via continue intraveneuze infusie en het gedurende een aantal 
uren verzamelen van urinemonsters. Met deze methode wordt het verschijnen 
van inuline in de urine gevolgd. Aangezien het lastig is om bij jonge kinderen 
nauwkeurig urine te verzamelen, kan als alternatief de plasma klaring van inuline 
worden bepaald. Het verdwijnen van inuline uit het plasma in de loop van 
de tijd wordt hierbij gevolgd. Bij deze methode worden geen urinemonsters 
verzameld. Inuline wordt via continue infusie (inuline continue infusiemethode) of 
eenmalige injectie (inuline single injectie methode) toegediend. Bij de continue 
infusiemethode wordt er vanuit gegaan dat de snelheid van uitscheiding gelijk is 
aan de infuussnelheid vanaf het moment dat de plasma concentratie van inuline 
constant is [1]. De tijd om tot een constante inuline plasma concentratie te komen 
is kritisch en varieert van 1 tot 12 uur [9]. De inuline single injectie methode, 
waarbij inuline als bolus injectie intraveneus wordt toegediend en op een aantal 
tijdstippen bloedmonsters worden afgenomen voor het opstellen van de plasma 
verdwijningscurve, is in een aantal opzichten praktischer. De totale periode voor 
het bepalen van de inuline plasma klaring kan beperkt blijven tot 4 uur en er hoeft 
85
slechts eenmaal geprikt te worden voor het 
inbrengen van een afname-canule. Voor 
het nauwkeurig beschrijven van de plasma 
verdwijningscurve was tot voor kort een groot 
aantal bloedmonsters nodig (10-12). Door 
het opstellen van gelimiteerde en optimale 
bemonsteringsschema’s voor de inuline single 
injectie methode is het aantal af te nemen 
bloedmonsters sterk gereduceerd, waardoor de 
methode patiëntvriendelijker is geworden [2, 3]. 
In het Erasmus MC-Sophia is bij 24 kinderen de 
inuline single injectie methode vergeleken met 
de continue infusiemethode, wat tot dan toe 
de gebruikelijke methode was voor het bepalen 
van de GFR. De inuline plasma klaring bepaald 
met de single injectie methode was gemiddeld 
iets hoger (9.7 mL/min/1.73m2), waarbij het 
verschil tussen de methoden kleiner was bij 
een slechtere nierfunctie (GFR < 50 mL/min/
1.73m2) [10].  
Voor de dagelijkse praktijk is het bepalen 
van de urine klaring of de plasma klaring 
van inuline ongeschikt omdat het relatief 
veel tijd kost. In de kliniek wordt daarom in 
het algemeen alleen gebruik gemaakt van 
endogene markers (kreatinine of cystatine C). 
Kreatinine, een afbraakproduct van spieren, 
is geen ideale marker omdat de kreatinine 
plasma concentratie afhankelijk is van de 
spiermassa van de patient. Een andere reden 
waarom kreatinine geen geschikte parameter 
is voor het volgen van de nierfunctie is 
dat het niet alleen glomerulair gefiltreerd 
wordt maar ook via tubulaire secretie wordt 
uitgescheiden. De mate van tubulaire 
secretie van kreatinine is niet constant: de 
uitscheiding van kreatinine via tubulaire 
secretie ten opzichte van de totale kreatinine 
uitscheiding neemt toe bij een slechtere 
nierfunctie. Dit leidt in het geval van een 
slechte nierfunctie tot overschatting van de 
GFR [8]. Cystatine C, eveneens een endogene 
marker, is een eiwit (molecuulgewicht 13.3 
kDa), dat het enzym cysteïne proteïnase remt. 
Het is een relatief nieuwe marker voor de 
GFR. Het wordt met een constante snelheid 
aangemaakt in alle kernhoudende cellen en 
wordt vrij gefiltreerd in de glomerulus. Door 
tubulaire epitheelcellen wordt het vervolgens 
teruggeresorbeerd en gekataboliseerd  
[11, 12]. Uit verschillende onderzoeken blijkt 
cystatine C geen betere GFR marker te zijn in 
vergelijking met kreatinine [13]. Tevens is de 
bepaling van cystatine C aanzienlijk duurder 
en de ervaring met kreatinine veel groter, 
waardoor cystatine C geen alternatief is voor 
kreatinine als marker voor GFR.      
In de dagelijkse praktijk wordt de GFR geschat 
aan de hand van een formule gebaseerd  
op de kreatinine concentratie. De formule is 
opgebouwd uit de ratio lichaamslengte  
(LH; cm) van het kind en de plasma kreatinine 
concentratie (Pcr; μmol/L), vermenigvuldigd 
met een een constante (factor k): 
 
Voor k zijn in de loop van de tijd verschillende 
waarden gedefinieerd: k = 38 (Counahan et 
al.), k = 40 (Morris et al.) en k = 48.7 (Schwartz 
et al.) [14-16]. In de praktijk wordt vaak de 
waarde k = 40 gehanteerd. Hierbij dient te 
GFR (mL/min/1.73m2) =              
k x LH
Pcr
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worden opgemerkt dat het aan te raden is om lokaal de waarde voor k te bepalen, 
omdat de waarde samenhangt met de bepalingsmethode die als referentie wordt 
gebruikt voor het nauwkeurig volgen van de nierfunctie en de patiëntenpopulatie 
[17]. Men dient zich te realiseren dat de GFR berekend aan de hand van 
bovenstaande fomule te onnauwkeurig is om de nierfunctie nauwkeurig te volgen, 
zoals gewenst is bij bijvoorbeeld kinderen met progressieve nierinsufficiëntie of 
kinderen die een niertransplantatie hebben ondergaan. Pierrat et al. rapporteerde 
een overschatting van 20-25% voor de GFR berekend aan de hand van de formule 
ten opzichte van de urine klaring van inuline (n=198, leeftijd: 3-19 jaar) [18].  
In een eigen onderzoek werd in meer dan 40% van de patiënten een verschil  
groter dan 10 mL/min/1.73m2 tussen de GFR geschat aan de hand van bovenstaande 
formule en de inuline plasma klaring, bepaald zoals beschreven in dit artikel, 
gevonden (n=48, leeftijd: 5-18 jaar) [17].
Indien een nauwkeurige meting van de GFR gewenst is, gaat de voorkeur uit naar 
het bepalen van de plasma klaring van inuline met de single injectie methode 
met een beperkt aantal afnametijdstippen. Deze methode is praktischer en 
patiëntvriendelijker dan de ‘gouden standaard’ methode waarbij urineverzameling 
noodzakelijk is. In dit onderzoek werd de inuline single injectie methode voor het 
bepalen van de GFR bij kinderen gevalideerd. 
Voor patiënten met een GFR < 75 mL/min/1.73m2 gaf de inuline single injectie 
methode met 4 afnametijdstippen (10, 30, 90 en 240 min) een inuline plasma 
klaring, die gemiddeld 0.6 mL/min/1.73m2 lager was dan de inuline plasma klaring 
gebaseerd op 11 afnametijdstippen. Het gevonden verschil in inuline klaring was 
niet statistisch significant. Bij patiënten met een GFR > 75 mL/min/1.73m2 was 
sprake van een lichte bias, die niet klinisch relevant was. Aangezien het met name 
bij een lage GFR van belang is dat een kleine verandering in nierfunctie (circa 
10 mL/min/1.73m2) kan worden waargenomen, kan op grond van de gevonden 
resultaten worden geconcludeerd dat de inuline single injection methode met 
4 afnametijdstippen een geschikte methode is voor het bepalen van de GFR bij 
kinderen. Zo kan met deze methode de nierfunctie nauwkeurig worden gemeten 
bij kinderen, bij wie door bijvoorbeeld afwijkende lichaamsproporties de kreatinine 
plasma concentratie niet betrouwbaar is. Tevens is het een relatief eenvoudige 
methode om de nierfunctie te bepalen bij bijvoorbeeld kinderen met progressieve 
nierinsufficiëntie of bij kinderen die een niertransplantatie hebben ondergaan. 
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to develop a formula that better explained 
the relationship between patient factors and 
GFR. Bias and precision of all formulae were 
calculated for the validation data set. 
In the index data set a value of 41.2 was found 
for k, which was close to the value k = 40 
(Morris). Both formulae estimated GFR well 
(bias< 5%; precision: 25%). Further modeling 
of the relationship between patient factors 
and GFR did not improve the predictive 
performance.
In our hospital GFR was best estimated 
by the formula with k = 40 and 41.2. It is 
recommended to assess the optimal value 
for k locally. 
ABSTRACT
Glomerular filtration rate (GFR) in children 
can be estimated by GFR = k x BH / Pcr (BH: 
body height (cm); Pcr: plasma creatinine 
concentration (μmol/L)). For k, several values 
have been reported: k = 38 (Counahan), 40 
(Morris) and 48.7 (Schwartz). In this study the 
predictive performance of these formulae 
was compared with that of newly developed 
formulae. 
GFR measurements based on inulin 
concentration time curves were divided into 
an index (n=58) and a validation data set 
(n=48). In the index data set a value for k was 
derived by application of nonlinear mixed-
effect modeling. This approach was also used 
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INTRODUCTION
In clinical practice the glomerular filtration rate (GFR) is determined to evaluate 
renal function in suspected renal diseases and to monitor renal function during 
treatment of renal diseases. The urinary clearance of inulin with continuous 
intravenous infusion of inulin is regarded as the gold standard to determine GFR in 
children [1]. However, this method requires an intravenous infusion of inulin and 
timed urine collections over a period of several hours, which is cumbersome. In 
smaller children it also requires bladder catheterization. For daily practice formulae 
using the creatinine plasma concentration are widely employed to estimate GFR in 
children [2]. Estimates for GFR can be obtained by multiplication of the ratio of the 
child’s body height (BH; cm) and the plasma creatinine concentration (Pcr; μmol/L) 
by a constant (k) [3-5]: 
Various values of k have been reported: k = 38 (Counahan et al.), k = 40 (Morris et 
al.) and k = 48.7 (Schwartz et al.). Schwartz et al. differentiated various values of k for 
infants and children of different ages, since the relationship between muscle mass 
and body height changes with age [6-8]. 
Most formulae for estimation of GFR have been created by using linear regression 
(plotting the reciprocal of creatinine concentration against the measured GFR). 
Interestingly, Léger et al. have recently used nonlinear mixed-effect modeling 
(NONMEM) to assess the relationship between patient factors and the plasma 
clearance of 51Cr-EDTA in 64 children [9]. In NONMEM both fixed effects (i.e. 
relationships between pharmacokinetic parameters and patient factors) and 
random effects (i.e. inter- and intra-patient variability) are evaluated.  
In the current study an algorithm was developed based on NONMEM analysis of 
inulin plasma concentration in pediatric patients. Using this population approach 
a k-value was derived for the formula as mentioned above (formula A). Also, it was 
investigated whether estimation of GFR could be improved by including more 
patient factors in the algorithm. The predictive performance (i.e. bias and precision) 
of the newly developed algorithms was compared with the formulae reported 
earlier by Counahan et al., Morris et al. and Schwartz et al. 
GFR =                   (formula A)             
k x BH
Pcr
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METHODS
Patients
All patients were seen at the outpatient clinic 
of the Erasmus MC - Sophia Children’s Hospital 
of Rotterdam for routine determination of the 
renal function in the period April 2000 and 
August 2004.
One group of pediatric patients (index data 
set; n=42; 58 studies) was used to determine 
the optimal value for k and  to develop a 
formula that better explained the relationship 
between patient factors and GFR. The second 
group of pediatric patients (validation 
data set; n=35; 48 studies) was applied to 
compare the predictive performance of the 
newly developed algorithms with the earlier 
reported formulae.
Study design
In all patients the single injection method was 
applied to determine the plasma clearance 
of inulin [10, 11]. This method is used as 
standard method for routine determination 
of the renal function in the Sophia Children’s 
Hospital. Inulin (polyfructosan, Inutest®, 
Fresenius Pharma, Graz, Austria) was infused in 
a dose of 5000 mg/1.73 m2 body surface area 
(maximum dose 5000 mg), at a constant rate 
over 30 seconds. After administration of inulin 
at least 4 blood samples were taken during 
a time window of 240 minutes after injection 
(10 / 30 / 90 / 240 minutes after injection). 
Inulin plasma clearance values were obtained 
by fitting of the individual curves to a two-
compartment model using extended least 
squares estimation in NONMEM [12]. GFR was 
corrected for body surface area (mL/min/1.73m2).
  
Biochemical assay
The inulin plasma concentration was 
measured enzymatically on the Hitachi 912 
(Roche Diagnostics) [13, 14]. The coefficient 
of variation for this method was 6.9% at 136 
mg/L and 1.9% at 725 mg/L. The assay was 
linear up to 2100 mg/L. The creatinine plasma 
concentration was measured enzymatically on 
the Hitachi 912 (Roche Diagnostics).
Index data set: development of an 
algorithm to estimate GFR 
Algorithms for GFR were derived by performing 
a population pharmacokinetic analysis in the 
index data set using the nonlinear mixed-effect 
modeling program NONMEM (double precision; 
version V, level 1.1). The pharmacokinetics  
of inulin was described on the basis of a  
2-compartment model. Inulin pharmacokinetic 
parameters of the model were estimated in 
terms of clearance (CL), central volume of 
distribution (V1), peripheral volume of distribution 
(V2) and intercompartmental clearance (Q). A 
proportional error model was used to describe 
the inter-individual variability. The residual 
intra-individual variability was modeled with a 
combined additive-proportional error model. 
An estimate for k in formula A was obtained 
by modeling the inulin plasma concentration 
time profiles of the index data set. In a more 
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extensive analysis the relationship between CL (i.e. GFR) and the following factors 
was tested: Pcr (μmol/L), age (AGE, years), body surface area (BSA, m
2), body weight 
(WT, kg), height (HT, cm), and sex (male / female). In the basic NONMEM model all 
factors were introduced simultaneously using:
(formula B), in which θ1 is the clearance of a female patient with median Pcr, AGE, 
BSA, WT and HT, and θ2, θ3, θ4, θ5 and θ6 are exponentials. θ7 is the fractional 
increase of clearance in males (i.e. SEX=1) when compared to females (i.e. SEX=0). 
The patient factors were separately eliminated from the basic model. A factor was 
retained when exclusion significantly (p<0.01) worsened the fit of the model. The 
main criterion of decision was the likelihood ratio test [15]. 
Validation data set: predictive performance of the formulae to 
estimate GFR
Agreement between the estimated GFR and the plasma clearance of inulin was 
evaluated by calculating the predictive performance and creating Bland-Altman 
plots for the validation data set. The predictive performance includes the mean 
relative prediction error (MPE%) and its 95% confidence interval as a measure of 
bias, and the root mean squared relative prediction error (RMSE%) and its 95% 
confidence interval as a measure of imprecision [16]. MPE%, RMSE% and the 
standard error for MPE% were defined as follows:
CL=θ1x PcrmedianPcr(                   )
θ2 AGE
medianAGEx(                    )
θ3 BSA
medianBSAx(                    )
θ4 WT
medianWTx(                    )
θ5 HT
medianHTx(                    )
θ6
x θ7sex
MPE% =              x 100%
Σ pei
n
i=1
n
SE% =                           x 100%
Σ (pei - MPE)2
n
i=1
n x (n - 1)
RMSE% =                 x 100%
Σ (pei )2
n
i=1
n
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in which n is the number of clearance pairs 
(i.e. reference and estimated values) and pe is 
the prediction error (pe = ln (GFRestimated) 
- ln (GFRinulin)). The log transformation was 
performed to avoid bias in favour of high 
values. Ninety five percent confidence interval 
of RMSE% was obtained by calculating 95% 
confidence interval of mean squared relative 
prediction error and extracting the root. 
Ideally MPE is 0 and  RMSE is < 30%. 
For the Bland-Altman plot the difference in 
estimated GFR and inulin plasma clearance 
was plotted against the mean GFR as 
described by Bland and Altman [17]. The 
statistical analysis was made by using 
GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, USA).
 
RESULTS
Patient characteristics are summarized in 
Table I. In the index dataset 14 patients were 
included twice and in 1 patient the renal 
function was determined 3 times, while  
13 patients were included twice in the 
validation data set. These patients were 
included as new patients since GFR varied  
and the time between the measurements  
was at least 1 year.   
In the basic population model (index data set) 
no correlation between CL and patient factors 
was assumed and the following population 
estimates were obtained: CL = 37.4 mL/min, 
V1= 6.81 L, V2 = 4.35 L and Q= 119 mL/min. 
Unexplained inter-patient variability for CL 
was 118%. Adding body height and plasma 
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creatinine concentration as determinants 
for the plasma clearance of inulin in the 
population model (formula A) significantly 
improved the fit. The unexplained inter- 
patient variability was reduced to 24% and  
k was 41.2 ± 5.6.
Unexplained inter-patient variability was 
further reduced to 17% when all patient 
factors were included in the population model 
(formula B). Removal of the patient factors age 
(AGE), weight (WT), body surface area (BSA) 
and gender (SEX) did not significantly worsen 
the population model (unexplained inter-
patient variability in clearance: 18%). For a 
patient with a median body height of 146 cm 
and a median plasma creatinine concentration 
of 118 µmol/L the clearance was 51.2 ±  
1.9 mL/min/1.73m2. Exponents for body height 
and plasma creatinine concentration were 
0.489 ± 0.160 and -0.736 ± 0.071, respectively. 
Table II presents the formulae to estimate GFR.
The predictive performance of the tested 
formulae for the validation data set is given in 
Table III. Figure 1 shows the 95% confidence 
interval of the bias and precision for the 
tested formulae in the validation data set. 
GFR estimated by the formula developed 
from the index data set by NONMEM (formula 
B) showed a bias of –4.3 % and a precision 
of less than 30%. Using k = 41.2 resulted in 
GFR estimates which were not statistically 
different from the reference values (i.e. inulin 
plasma clearances). The formula according 
to Counahan et al. and Morris et al. was not 
significantly biased and the precision was 
around 25%. 
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Table I. Patient characteristics
  Index data set  Validation data set
 
Number of studies 58 48
Patients 42 35
 male 27 23
 female 15 12
Age (years)
 median 15  13 
 range 4-20 5-18
Weight (kg) 
 median   45 47 
 range 13-89 20-82
Height (cm)
 median  150  152 
 range 97-179 106-186
BSA (m2)
 median  1.35  1.44 
 range 0.59-2.05 0.75-1.98
Creatinine concentration (μmol/L)
 median   87 89 
 range 19-660 35-434
Plasma clearance of inulin (mL/min/1.73m2)
 median  65 71 
 range 6-172 7-158
 Disorders
 kidney transplantation 35 28
 other disorders 7 7
 
BSA: Body Surface Area
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Table II. Formulae to estimate GFR
 
Earlier reported formulae:     
 
 Counahan et al.3  
 Morris et al.4    
 Schwartz et al.5  
 Léger et al.9  
Formulae developed from index data set:
 Formula A  
 Formula B  
 
  
BH: body height (cm); Pcr: plasma creatinine concentration (μmol/L); BW: body weight (kg) 
GFR(mL/min/1.73m2) =
38 x BH
Pcr
GFR(mL/min/1.73m2) =
40 x BH
Pcr
GFR(mL/min/1.73m2) =
48.7 x BH
Pcr
GFR(mL/min) =
56.7 x BW + 0.142 x BH2
Pcr
GFR(mL/min/1.73m2) =
41.2 x BH
Pcr
GFR(mL/min/1.73m2) =
51.2 x 
          Pcr  0.736
           118
 BH   0.489
146
(      )
(      )
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Table III. Predictive performance of the formulae to estimate GFR
  
   Validation data set (n=48)
Earlier reported formulae:  
 
 Counahan et al. (k = 38)3 
  Bias (%)  [95% CI]  -5.9 [–13,1.5]
  Imprecision (%) [95% CI] 26 [20,31] 
 Morris et al. (k = 40)4 
  Bias (%)  [95% CI]  -1.1 [-8.5,6.4]
  Imprecision (%) [95% CI] 25 [19, 31]
 Schwartz et al. (k = 48.7)5
  Bias (%)  [95% CI]  19 [11, 26] 
  Imprecision (%) [95% CI] 31 [23, 38]
 
 Léger et al.9 
  Bias (%)  [95% CI]  19 [11, 27]
  Imprecision (%) [95% CI] 34 [25, 41]
Formulae developed from index data set:
 Formula A (k = 41.2) 
  Bias (%)  [95% CI] 1.9 [-5.5,9.3]
  Imprecision (%) [95% CI] 25 [18,31]
 Formula B (NONMEM)  
  Bias (%)  [95% CI] -4.3 [-12,3.9]
  Imprecision (%) [95% CI] 28 [19,36]
Bias: mean relative prediction error (MPE)
Imprecision: root mean squared relative prediction error (RMSE)
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Formula B (NONMEM)
Formula A (k=41.2)
Léger
Schwartz
Morris
Counahan
-15 -10  -5  5 10 15 20 25 30
Bias (%)
Formula B (NONMEM)
Formula A (k=41.2)
Léger
Schwartz
Morris
Counahan
0 10 20 30 40 50
Imprecision (%)
Figure 1
95% Confidence interval of the bias (a) and imprecision (b) for the tested formulae in the 
validation data set (n=48).
a.
b.
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Table IV. Number of patients in the validation data set (n=48) with a 
difference between the estimated GFR and reference GFR  
(i.e. inulin plasma clearance) > 10 mL/min/1.73m2
 
  Number of patients (%)
Earlier reported formulae:     
 
 Counahan et al.3 26 (54) 
 Morris et al.4 22 (46)
 Schwartz et al.5 30 (63)
 Léger et al.9 28 (58)
Formulae developed from index data set:
 Formula A (k = 41.2)  21 (44)
 Formula B (NONMEM) 29 (60)   
In contrast, the formula of Schwartz et al. showed a significant bias (bias: 19%; 95% 
CI: 11-26). Also, a significant overestimation was observed for the formula according 
to Léger et al. (bias: 19%; 95% CI: 11-27). 
Figure 2 shows the Bland-Altman plots for the estimated GFR and the inulin plasma 
clearance. The mean difference between estimated and reference GFR varied from 
–0.97 for the formula of Morris et al. to 15 mL/min/1.73m2 for the formula according 
to Léger et al. For all the formulae it was remarkable that the difference between 
estimated GFR and the reference inulin plasma clearance was larger than 10 mL/
min/1.73m2 in more than 20 patients (range: 44-63%, Table IV). 
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Figure 2
Bland-Altman plots of the estimated GFR (GFR estimated) and the reference GFR (inulin plasma 
clearance, GFR inulin) (      mean difference).
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DISCUSSION
In daily clinical practice formulae based on the creatinine plasma concentration  
are widely employed to estimate GFR in children. Estimates for GFR can be obtained 
by multiplication of the ratio of the child’s body height and the plasma creatinine 
concentration by a constant k. In this study an algorithm was developed based  
on NONMEM analysis of inulin plasma concentration in pediatric patients.  
The predictive performance of the newly developed algorithms was compared  
with the earlier reported formulae. 
The formula with k = 41.2 and the formula of Morris et al. (k = 40) resulted in the 
best predictive performance with a bias less than 5% and a precision of around 
25%. The formula developed from the index data set by more extensive evaluation 
of patient factors did not produce a better predictive performance. Application 
of the formulae of Schwartz et al. (k = 48.7) and Léger et al. yielded a significant 
overestimation of GFR.  
The formula of Counahan et al. and Morris et al. resulted in a better predictive 
performance in comparison with the formula according to Schwartz et al. The 
former formulae are based on the plasma clearance of 51Cr-EDTA, while the formula 
according to Schwartz et al. was derived from the urinary clearance of creatinine. 
To calculate the predictive performance of the formulae in the validation data set, 
the inulin plasma clearance was used as reference clearance. In general, the plasma 
clearance of 51Cr-EDTA with single injection agreed well with the plasma clearance 
of inulin [18], while the urinary clearance of creatinine overestimated the inulin 
clearance especially at low levels of GFR due to tubular secretion [19, 20]. So it was 
expected that the formula of Morris et al. and Counahan et al. produced a better 
estimate of GFR than the formula according to Schwartz et al. The formula of  
Morris et al. predicted GFR better than the formula according to Counahan et al.  
(bias –1.1 vs –5.9%). Differences in patients’ characteristics or variation in the 
method for analysis, can possibly account for this difference.  
The formula developed from the index data set by more extensive evaluation of 
patient factors (NONMEM-analysis) produced a minor predictive performance 
compared with the formula based on body height, plasma creatinine concentration 
and the constant k = 40 or 41.2. This finding is not in agreement with our 
expectation, since it was suggested that including more patient factors results in a 
higher predictive performance. However, for daily practice it is very advantageous 
that a less complicated formula can be used to estimate GFR.
The formula according to Léger et al. overestimated the inulin plasma clearance. 
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This can be attributed to the use of different 
methods to measure GFR. In that study the 
51Cr-EDTA plasma clearance was used as 
reference method, while we applied the inulin 
plasma clearance. However, good agreement 
between the inulin and the 51Cr-EDTA plasma 
clearance was reported, but only if a two-
compartment model was applied to construct 
the plasma concentration-time decay curve 
of 51Cr-EDTA [18]. In the study of Léger et al. 
a one-compartment model was used. Aperia 
et al. demonstrated that a one-compartment 
analysis of 51Cr-EDTA plasma clearance resulted 
in a significantly higher GFR. Theoretically it 
is possible that if the formula according to 
Léger et al. was based on a two-compartment 
analysis the predictive performance of that 
formula would have been better. 
Since many years the impact of creatinine 
assays on the difference between estimated 
GFR and reference GFR has been discussed 
in numerous articles. Calibration bias in 
measuring serum creatinine concentration 
as well as pseudo-creatinine contribution of 
proteins (protein error) has been described 
[21, 22]. In our study the creatinine 
concentration was measured enzymatically, 
while the creatinine concentration in the 
studies of Morris et al, Counahan et al., 
Schwartz et al. and Léger et al. was measured 
non-enzymatically. As a consequence we 
could not exclude calibration bias. The protein 
error was eliminated by using an enzymatic 
method for creatinine measuring. 
Several studies have been published 
describing formulae to estimate GFR in 
different patient populations. Paap et al. 
compared 10 formulae to estimate GFR with 
the 24-h urinary clearance of creatinine 
in children with varying degree of renal 
dysfunction (n=22, 7-16 years of age) [23]. 
Formulae based on the ratio of the child’s 
body height and the plasma creatinine 
concentration, multiplied by a constant 
k, were tested, as well formulae which are 
applied in adults (for example formula of 
Cockroft and Gault). The formula with k = 46 
had the best predictive performance, although 
the predictive performance was worse in 
patients with a lower GFR (GFR <30 mL/
min/1.73m2). Paap et al. found a higher value 
for k since the urinary clearance of creatinine 
was used as reference method. As mentioned 
above the urinary clearance of creatinine 
overestimated the inulin clearance. As a 
consequence a higher value for k is required.  
Recently, Hellerstein et al. compared the 
formula of Léger et al. with the formula based 
on the ratio of the child’s body height and the 
plasma creatinine concentration. The optimal 
value for k was determined locally (k = 44 
for girls and boys younger than 13 years and 
k = 52 for boys older than 13 years; n=216, 
4.8-21 years of age) [24]. The formula of Léger 
et al. was not superior to the GFR calculated 
with k = 44 or 52. However, in the study of 
Hellerstein et al. the values for k were derived 
from and tested in the same data set, which 
is statistically incorrect. An independent data 
set has to be used for validation, since using 
one data set for developing and testing always 
results in a good performance. We applied an 
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index data set to develop the algorithms and tested the algorithms by calculating 
the predictive performance in the validation data set. 
The present study was performed in patients older than 4 years and most of them 
had a kidney transplant. It is not clear what the effect of this is on the optimal value 
of k. Theoretically it is possible that for patients without a kidney transplant the 
optimal k value differs. It would be interesting to evaluate the formula with k = 40 
and 41.2 in children without a kidney transplant. 
We only tested the constant k = 48.7 in the formula according to Schwartz et al. 
and did not apply a higher value of k with increasing age, since for daily practice 
it is preferred to use one value of k for all ages. A second reason why only k = 48.7 
was tested, was that applying various values for k also resulted in an overestimation 
of GFR (n=198, 3-19 years of age, mean difference in GFR: 20 mL/min/1.73m2) 
[25]. Furthermore, GFR estimated by the formula with k = 48.7 showed already an 
overestimation, this overestimation would only be larger if for boys older than 13 
years of age a higher value of k (k = 61.9) was applied.  
One has to realize that the formulae to estimate GFR can only be applied for clinical 
daily practice. The formulae are too imprecise for an accurate determination of GFR 
as desired in a research setting. In trials designed to improve graft function it is 
important to be able to detect small improvements in GFR (for example  
10 mL/min/1.73m2). Pierrat et al. reported an overestimation of 20-25% for the 
formula according to Schwartz et al. [25]. We found that the difference between 
estimated GFR and inulin plasma clearance for all formulae was larger than 10 mL/
min/1.73m2 in more than 40% of the patients in the validation data set. Therefore 
the formulae cannot replace the classical method for determination of GFR.
In conclusion, in this study GFR was best estimated by the formula with a k value of 
40 and 41.2. Introduction of more patient factors resulted in a formula, which was 
not better than the formula with a k value of 40 or 41.2. However, it is important to 
realize that these results are closely linked with the method, which was used for an 
accurate determination of GFR (reference method), and the population of patients. 
As a consequence it is recommended to assess the optimal value for k locally. 
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was calculated as ([A]-[V]) / [A], in which A is the 
plasma concentration of the compound from the 
abdominal aorta, and V is the plasma concentration 
of the compound from the renal vein.
The mean difference between the renal 
extraction ratio of cystatin C and that of  
125I-iothalamate was 0.002. The 95% confidence 
interval for the mean difference was -0.036 to 
0.032, which was not statistically significant. 
However, the limits of agreement were large 
(–0.271 and 0.267).  
The mean renal extraction of cystatin C was 
in agreement with the mean renal extraction 
of 125I-iothalamate in hypertensive patients, 
however a very large variation was found. 
Therefore, the use of cystatin C to estimate 
GFR is limited.   
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ABSTRACT 
Several markers are available to estimate the 
glomerular filtration rate (GFR) in patients. 
Cystatin C is a relatively new marker and 
has been suggested as an alternative for 
creatinine. Numerous studies have been 
performed to evaluate the usefulness of 
cystatin C to estimate GFR. The aim of this 
study was to compare the renal extraction 
of cystatin C with that of 125I-iothalamate in 
hypertensive patients.
Forty hypertensive patients with unilateral 
renal artery stenosis, and who used at  
least two antihypertensive agents, were
 studied. For the determination of the renal 
extraction ratio, blood samples were drawn 
simultaneously from the renal vein and the 
abdominal aorta. The renal extraction ratio 
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INTRODUCTION
The ability to measure renal function accurately is essential for evaluating 
patients with suspected renal diseases and for studying changes in renal function. 
Several markers are available to estimate the glomerular filtration rate (GFR). 
Creatinine is widely used to estimate GFR. It is a metabolic product of creatine 
and phosphocreatine in the muscle and its production is proportional to the total 
muscle mass. This leads to a variation in serum creatinine concentration across  
age, gender, race, nutritional status and body composition that is independent  
from changes in GFR. Moreover, creatinine is not only filtered by the glomerulus, 
but also secreted by the proximal tubule. As a consequence the GFR based on 
the plasma creatinine concentration is overestimated, particularly at lower GFR. 
As a result, studies with alternative markers for the estimation of GFR have been 
performed. Cystatin C is a relatively new marker and has been suggested as an 
alternative for creatinine [1, 2]. Cystatin C is a proteinase inhibitor with a molecular 
weight of 13.3 kDa and is produced by all nucleated cells. It is freely filtered by the 
glomerular membrane, reabsorbed and completely metabolized in the proximal 
tubule and does not return to the circulation [3]. Several studies have been 
performed to evaluate the usefulness of cystatin C to estimate GFR [3-7].  
As cystatin C is metabolized in the tubule, it is not possible to determine the urinary 
clearance of cystatin C. Therefore, we applied the renal extraction ratio of cystatin C 
to evaluate whether cystatin C is a useful to estimate GFR. The renal extraction ratio 
is a parameter for renal function and expresses the glomerular filtration and tubular 
handling (tubular secretion and / or reabsorption) of a substance. 
The aim of this study was to compare the renal extraction of cystatin C with that of 
125I-iothalamate in hypertensive adults.
METHODS
Patients
We studied 40 consecutive patients with suspected unilateral renal artery stenosis. 
All patients had a diastolic blood pressure higher than 95 mmHg and used at least 
two antihypertensives. The study was approved by the hospital review board and 
done during the diagnostic work-up for renal artery stenosis. Renal function was 
measured using the constant infusion clearance technique of 125I-iothalamate 
without urine collections [8]. For the determination of the renal extraction ratio 
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blood samples were drawn simultaneously 
from the renal vein and the abdominal aorta 
in sodium citrate tubes; first at one side and 
immediately thereafter on the other. Before 
each blood sampling the correct positioning 
of the catheter in the renal vein was confirmed 
by X-ray control and oxygen saturation 
measurement. 
The renal extraction ratio of cystatin C 
(Ecyst C) and 125I-iothalamate (Ethal) were 
calculated as ([A]-[V]) / [A], in which A is the 
plasma concentration of the compound from 
the abdominal aorta, and V is the plasma 
concentration of the compound from the 
renal vein. 
Biochemical assay
Plasma samples were stored at -20°C until 
analysis. Cystatin C was measured in triplicate 
using a fully automated particle enhanced 
immuno turbidimetric method (DAKO Cystatin 
C PET kit, Copenhagen, Danmark). The assay 
was performed on a Hitachi 912 auto-analyzer 
(Roche Diagnostics, Basel, Switzerland). Inter- 
and intra-assay variation, calculated from the 
control samples with assigned values of 1.4 
and 2.8 mg/L, was 11.3 and 5.6%, respectively. 
A concentration of triglycerides > 4 mmol/L 
interferes with the assay for cystatin C, 
therefore the triglycerides concentration was 
measured in all samples.
Statistical analysis
Data are presented as mean ± SD. Agreement 
between Ecyst C and Ethal was evaluated 
as described by Bland and Altman [9]. The 
limits of agreement represent the range 
around the mean difference between both 
methods in which 95% of the values will be 
found (mean difference ± 1.96xSD). The 95% 
confidence intervals of the mean difference 
were calculated by the mean difference ± 
t x  standard error of the mean difference, 
in which t is the appropriate point of the t 
distribution with n-1 degrees of freedom. 
The statistical analysis was made by using 
GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, USA). 
RESULTS
Forty hypertensive patients with unilateral 
renal artery stenosis were studied (male / 
female: 21 / 19; mean age: 55 ± 13 years). 
All plasma samples had a triglycerides 
concentration lower than 4 mmol/L. 
The mean plasma clearance of 125I-iothalamate 
was 61 ± 21 mL/min/1.73m2 and ranged from 
27 to 108 mL/min/1.73m2. For 1 patient the 
plasma clearance of 125I-iothalamate was not 
available. In Figure 1 the relationship between 
the reciprocal cystatin C concentration and 
the plasma clearance of 125I-iothalamate is 
shown. The squared correlation coefficient 
was 0.538.  
In total 80 samples of the left and right kidney 
from 40 patients were available to determine 
the renal extraction ratio of cystatin C.  
In 16 cases the sample volume was insufficient 
for analysis in triplicate. The range of renal 
extraction ratios varied from 0.01 to 0.54 for 
cystatin C and 0.01 to 0.33 for 125I-iothalamate. 
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Figure 1
Correlation between the reciprocal cystatin C concentration and the plasma 
clearance of 125I-iothalamate (39 patients).
Figure 2 shows the Bland-Altman plot for Ecyst C and Ethal. Although the mean 
difference between Ecyst C and Ethal was small (0.002), the limits of agreement for 
the mean difference were large (–0.271 and 0.267). The 95% confidence interval for 
the mean difference was -0.036 to 0.032, which shows that the mean difference was 
not statistically significant. 
From the first 20 patients the extraction ratio of creatinine was also available.  
Figure 3 represents the Bland-Altman plot for the renal extraction ratio of creatinine 
(Ecreat) and 125I-iothalamate (36 samples; mean difference: 0.014; 95% confidence 
interval of the mean difference: -0.011 to 0.039; limits of agreement: -0.131 and 0.159).
R2=0.538
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Figure 3
Bland-Altman plot of the renal extraction ratio of creatinine and that of  
125I-iothalamate (      limits of agreement) (36 samples from 20 patients).
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Bland-Altman plot of the renal extraction ratio of cystatin C and that of  
125I-iothalamate (      limits of agreement) (64 samples from 40 patients).
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DISCUSSION
This study represented the first direct measurement of renal extraction of cystatin 
C. We observed that the mean difference between the extraction ratios of cystatin 
C and 125I-iothalamate was not statistically significant. However, the limits of 
agreement showed a large range. In general, the renal extraction ratio shows a 
larger variation than the GFR, since a small variation in concentration has a large 
impact on the value of the extraction ratio. As the cystatin C concentration was 
measured at least in triplicate, it seems that this argument could not fully explain 
the observed variation. 
The large limits of agreement (i.e. variation in the renal extraction of cystatin C) 
suggest that the theory that cystatin C is readily filtered in the glomerulus (sieving 
coefficient of 1) and subsequently metabolized in the tubule is untrue. Given its 
molecular weight of 13.3 kD, which is greater than that of either creatinine  
(0,113 kD) or inulin (5.2 kD), the sieving coefficient of cystatin C may not equal 1. 
The observed relationship with the plasma clearance of 125I-iothalamate would  
than depend on, varying, tubular secretion. 
Following the introduction of cystatin C many positive results were reported.  
In contrast to creatinine, cystatin C showed a constant production rate. However, 
more recently it appears that the use of cystatin C to estimate GFR has also 
limitations [3]. We demonstrated that the renal extraction of cystatin C has a large 
variation. Several other investigators reported that the plasma concentration 
of cystatin C is not only altered by renal function but also by nonrenal factors. 
Changes in cystatin C concentration do not reflect changes in GFR in children 
with a renal transplant, which has been attributed to the use of (a large dose 
of ) glucocorticoids [3, 10-13]. It has also been reported that the concentration 
of cystatin C in patients with various types of cancer was increased irrespective 
of renal function [14]. However, it is not clear if this increase in cystatin C 
concentration was attributable to increased production rate or to decreased 
elimination [14, 15]. Knight et al. performed a multivariate analysis to identify  
factors influencing the serum cystatin C concentration. Older age, male gender, 
greater weight, greater height, current cigarette smoking, and higher serum C-
reactive protein levels were all independently associated with increased serum 
cystatin C concentrations [16]. Thyroid dysfunction also has an impact on plasma 
cystatin C concentration [17, 18].
115
The present study was performed in 
hypertensive patients who used two or 
more antihypertensive agents. It is not clear 
whether similar results will be found in non-
hypertensive patients, since its theoretically 
possible that antihypertensive agents (such 
as angiotensin converting enzyme inhibitors 
or angiotensin II antagonists) change the 
renal extraction of cystatin C. However, we 
compared the renal extraction ratio of cystatin 
C with that of 125I-iothalamate and the effect 
of the antihypertensive agents on glomerular 
filtration would equally affect both markers. 
Moreover, Knight et al. studied the effect 
of several factors on the serum cystatin C 
concentration and found that the presence of 
hypertension was not significantly associated 
with an increase in cystatin C concentration 
[16]. Therefore, the results can be extrapolated 
to other patient populations.
We conclude that the mean renal extraction 
of cystatin C was in agreement with the 
mean renal extraction of 125I-iothalamate in 
hypertensive patients, however a very large 
variation was found. Therefore, the use of 
cystatin C to estimate GFR is limited.   
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urinary excretion rate. The urinary clearance 
is calculated by dividing the urinary excretion 
rate of the marker by its plasma concentration. 
Both endogenous and exogenous markers 
can be used for the determination of the 
urinary clearance. Critical aspects of this 
method are complete emptying of the 
bladder, an accurate measurement of the 
urine volume for each clearance period and 
a precise recording of the duration of the 
urine collection period. The plasma clearance 
can only be performed with an exogenous 
marker. The plasma clearance of an exogenous 
marker can be determined by use of either a 
continuous intravenous infusion or a single 
bolus injection. The continuous infusion 
method is based on the concept that when 
the plasma concentration of the marker is 
constant (steady state concentration) and 
the volume of distribution is saturated with 
the marker (state of equilibration), the rate 
of excretion equals the rate of infusion. GFR 
can be calculated from the infusion rate, the 
concentration of the marker in the infusate 
and the plasma concentration of the marker. 
With the single injection method, a bolus 
injection of the marker is administered and 
blood samples are collected to construct a 
plasma concentration-time-decay curve.  
The plasma clearance of the marker is 
calculated from the dose and the Area Under 
the concentration-time Curve (AUC), using a 
classical pharmacokinetic approach.
Both the National Kidney Foundation of 
DETERMINATION OF THE 
GLOMERULAR FILTRATION RATE
Renal function tests are important to evaluate 
the progression of kidney disease and to 
monitor renal function during drug treatment. 
For the assessment of renal function the 
mechanisms responsible for the formation 
of urine, namely filtration, reabsorption and 
secretion, must be taken into consideration. 
The excretion of endogenous and exogenous 
substances is mainly regulated by glomerular 
filtration. Glomerular filtration rate (GFR) is 
considered the most important parameter to 
evaluate renal function and it is affected by 
most kidney diseases.
The ideal marker for the determination of GFR 
is physiologically inert, freely filtered in the 
glomerulus and neither secreted, reabsorbed, 
synthesized, nor metabolized by the kidney. 
Inulin, an exogenous polysaccharide, has 
all of the properties of an ideal marker and 
is considered the gold standard. Other 
substances to determine GFR are radio-
isotopes (for example 125I-iothalamate,  
51Cr-EDTA and 99mTc-DTPA) and iohexol, all 
exogenous markers, and the endogenous 
markers creatinine and cystatin C.
GFR can be determined by measuring the 
appearance of a marker in the urine (urinary 
clearance) or the disappearance of the marker 
from the blood (plasma clearance). The 
urinary clearance is defined as the volume 
of plasma from which the marker shoud be 
totally cleared to account for its excretion 
in the urine during a certain period of time. 
It always requires the measurement of the 
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the United States and the European Renal Association - European Dialysis and 
Transplant Association developed clinical guidelines with recommendations for 
the clinical assessment of kidney diseases in adults and children [1, 2]. In order to 
determine GFR, the European guidelines recommend to use only methods, that 
have been validated in patients with advanced renal failure. According to these 
guidelines, the preferred method to determine GFR in advanced renal failure is the 
mean of urea and creatinine clearance (with 24 hour urine collection). However, 
creatinine is not only filtered by the glomerulus but also secreted by the renal 
tubules, while the renal tubules absorb urea. The mean of urea and creatinine 
clearance is close to GFR. The U.S. National Kidney Foundation states that the 
most widely applied method to determine GFR in clinical practice is based on 
the 24-hour creatinine clearance or serum creatinine concentration. The accuracy 
of urine-based GFR determination depends on the patient’s ability to collect the 
urine  properly over a defined time. Failing to empty the bladder at the start of the 
collection, failing to collect all urine passed during the collection interval and errors 
in timing the interval are common sources of error. Adults can be instructed to 
minimize these errors (‘every drop of the urine has to be collected’), but in children 
it is cumbersome to collect the urine samples correctly. Bladder catheterization and 
making an ultrasonograph to check whether the bladder is empty can help, but 
such interventions are inconvenient to children. As a consequence, determination 
of the urinary clearance of a marker (for example creatinine) in children is not 
preferred. 
Determination of the plasma clearance of a marker is an alternative method 
to determine GFR  without collection of urine. The plasma clearance of inulin, 
radiolabelled markers (125I-iothalamate, 51Cr-EDTA, 99mTc-DTPA), non-radiolabelled 
iothalamate and iohexol can be determined in adults. Although inulin is considered 
as gold standard marker, in adults radiolabelled markers are commonly used since 
their measurement is relatively simple and very accurate. Potential safety drawbacks 
related to radiation exposure have led to a wide discussion around to use of these 
markers in children. Supporters of radiolabelled markers indicate that the exposure 
to radiation is limited and is not more than that of a radiograph. Opponents argue 
that one has to be careful with the use of radiolabelled markers in children and 
that there are good or even better alternatives (i.e. inulin). In general, the use of 
radiolabelled markers in children is limited. Therefore, the preferred marker to 
determine the plasma clearance in children is inulin and much experience has  
been gained with it in children. 
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The plasma clearance of inulin can be 
measured by use of either a continuous 
intravenous infusion or a single bolus 
injection. In the Sophia Children’s Hospital, an 
academic children’s hospital with 270 beds, 
the inulin plasma clearance with continuous 
infusion has been used as the standard 
method to determine GFR for many years. 
With this method, hospitalization is necessary 
for the duration of the inulin infusion and it 
requires three capillary blood samples. This 
makes the procedure complex, invasive and 
time-consuming. The single injection method 
can be performed in daycare, with only one 
venous puncture for the administration of 
inulin and for the collection of blood samples. 
An inulin bolus is administered intravenously 
and blood samples are collected up to 240 
min after injection. The inulin concentrations 
measured are used to construct a plasma 
concentration-time-decay curve. Ten to twelve 
blood samples are usually required for an 
accurate description of the curve. It is stressful 
for children to draw a lot of blood samples 
and therefore limited and optimal sampling 
strategies were introduced [3-5].  
The single injection method with blood 
samples taken at 10, 30, 90 and 240 minutes 
after administration and Bayesian analysis  
had an excellent accuracy and was on average  
9.7 mL/min/1.73m2 higher than the inulin 
plasma clearance determined with the 
continuous infusion method [6]. 
ESTIMATION OF THE 
GLOMERULAR FILTRATION RATE  
IN DAILY PRACTICE
For daily practice formulae including the 
creatinine plasma concentration and 
patient’s characteristics are widely employed 
to estimate GFR. Variation in creatinine 
production due to age- and sex-related 
differences in muscle mass has been 
incorporated in these formulae. It can be 
stated that the use of formulae including 
the creatinine concentration give more valid 
estimates of GFR than the serum creatinine 
concentration alone. The most frequently 
used formula to estimate GFR in adults is that 
of Cockroft and Gault, which includes age, 
body weight, gender and serum creatinine 
concentration [7]. This formula was developed 
in 1976 and was derived from the urinary 
creatinine clearance of 249 patients (mainly 
males; age: 18-92 years; mean GFR: 37 - 115 
mL/min depending on age). More recently 
the MDRD (Modification of Diet in Renal 
Disease) formula was developed for adults 
[8]. This formula was derived from 1070 
patients and validated in 558 patients with 
the urinary clearance of 125I-iothalamate as 
reference method (mean age: 50.6 ± 12.7 
years, mean GFR: 39.8 ± 21.2 mL/min/1.73m2). 
The original MDRD formula requires the 
variables serum creatinine, age, serum urea 
nitrogen, serum albumin, gender and race. 
An abbreviated version of the MDRD formula 
with serum creatinine, age, gender and race 
as variables has also been introduced, since 
the contributions of blood urea nitrogen 
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and serum albumin concentrations to the original formula were small [9, 10]. The 
Cockroft-Gault formula and the MDRD formula have been evaluated in different 
patient populations in numerous publications [1]. In general it can be said that 
the appropriateness of the formulae depends on the selected patients, the 
reference method to determine GFR and the assay to measure the serum creatinine 
concentration.
For children, estimates of GFR can be obtained by multiplying the ratio of the child’s 
body height (cm) and the plasma creatinine concentration (μmol/L) by a constant k. 
Various values of k have been reported: k = 38 (Counahan et al.), k = 40 (Morris 
et al.) and k = 48.7 (Schwartz et al.) [11-13]. Recently, algorithms to estimate GFR 
in children were developed based on NONMEM analysis [14, 15]. However, these 
algorithms with extensive evaluation of patient factors did not produce a better 
predictive performance compared with the formula based on body height, plasma 
creatinine concentration and the constant k = 40 [15]. There is debate over which 
value to use for k. It is recommended to assess the optimal value for k locally, since 
the value of k is closely linked with the method used for an accurate determination 
of GFR (reference method), and the population of patients. 
It is still unknown until which age a formula specially developed for children should 
be applied. As mentioned before the most common formulae to estimate GFR 
in children are based on the ratio of the child’s body height (cm) and the plasma 
creatinine concentration (μmol/L) multiplied by a constant k. These formulae were 
derived from children aged from 2 months - 14 years (Counahan), 2 - 14 years 
(Morris) and 6 months - 20 years (Schwartz). When the Cockroft-Gault formula was 
developed patients aged from 18 - 92 years were included, while for the MDRD 
formula patients aged from 18 - 70 years were recruited. These formulae for adults 
and children show a small overlap with respect to age. Pierrat et al. compared the 
Cockroft-Gault formula, the MDRD formula and the Schwartz formula with different 
values for k with the urinary clearance of inulin in 198 children [16].  
The children were divided into three age groups: < 8 years, 8 to 12 years and > 12 
years. In children over 12 years old (n=116) the Cockroft-Gault formula was close 
to the inulin clearance (mean difference of GFR circa 15 ml/min/1.73m2), but the 
difference was significant. The MDRD and the Schwartz formulae overestimated 
GFR. Nevertheless, the authors concluded  that the Cockroft-Gault formula could be 
used for children over 12 years of age. Paap et al. compared 10 formulae to estimate 
GFR with the 24-h urinary clearance of creatinine in children with varying degrees 
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of renal dysfunction (n=22, 7-16 years of 
age) [17]. Formulae based on the ratio of the 
child’s body height and the plasma creatinine 
concentration, multiplied by a constant k 
as well as the Cockroft-Gault formula were 
tested. The Cockroft-Gault formula was less 
accurate than formulae based on the ratio 
of the child’s body height and the plasma 
creatinine concentration. Unfortunately, no 
stratification by age was applied. Recently 
Filler et al. compared the Cockroft-Gault 
formula and the formula of Schwartz (k = 38 
for children younger than 13 years and girls 
older than 13 years; k = 48 for boys older than 
13 years) with the renal clearance of 99mTc-
DTPA in 262 children (1.0 - 18.9 years of age) 
[18]. A bias of - 19.0 ± 36.4% was found for the 
Cockroft-Gault formula compared with a bias 
of -12.8 ± 24.2% for the Schwartz formula in 
all patients. For boys older than 13 years both 
formulae showed a smaller bias (bias of 5.0 ± 
23.5% for the Cockroft-Gault formula; bias of 
-6.8 ± 24.0% for the Schwartz formula with  
k = 48). It was not clear whether the GFR 
estimate by the Cockroft-Gault formula was 
corrected for body surface area. 
In our data set (n=48) 5 patients had an age of 
> 16 years (n=4 aged 17 years and n=1 aged 
18 years). In all these patients the Cockroft-
Gault formula overestimated the inulin plasma 
clearance (mean estimated GFR was 87 
mL/min/1.73m2 vs mean reference GFR of 52 
mL/min/1.73m2) and the abbreviated MDRD 
formula also produced an overestimation 
(mean estimated GFR: 71 mL/min/1.73m2), 
however the number of patients was small. 
Based on these results, it is not simple to 
answer the question from which age formulae 
developed for adults should be applied. The 
decision should be made for each patient 
individually and only for children who passed 
the teenage years. It is also advisable to 
estimate GFR by both formulae if the renal 
function has to be followed over a prolonged 
period of time.    
COMPARISON OF TWO METHODS 
TO ESTIMATE THE GLOMERULAR 
FILTRATION RATE
In Chapter 2 - 5 several methods were 
compared to estimate GFR in children. 
Agreement between two methods was 
evaluated by calculating the predictive 
performance (bias and imprecision) and/or 
creating Bland-Altman plots. In the past, it 
was common to compute the correlation 
coefficient to evaluate the agreement 
between two measurement methods in the 
same subject. Sheiner et al. showed that a 
high correlation coefficient does not indicate 
an absence of over- or under prediction and 
can be quite misleading [19]. The correlation 
coefficient assesses the strength of the 
association along the best line between the 
two methods, but that line is not necessarily 
the line of identity, in which one is interested. 
If a correlation coefficient of 1 is found 
between an estimated and reference GFR and 
there is a systematic overprediction of  
50 mL/min/1.73m2 the method is still 
worthless. It is more accurate to evaluate the 
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predictive performance by calculating the mean relative prediction error (MPE) as 
a measure of bias and the root mean squared relative prediction error (RMSE) as 
measure of imprecision [19].
Bland and Altman have devised a simple way of graphically comparing two 
methods: the difference between two methods is plotted against the mean of 
the two methods [20]. The advantage of this method is that a trend in scatter can 
be observed easily. The mean difference between the two methods and its 95% 
confidence intervals can be calculated. The limits of agreement represent the range 
around the mean difference between the two methods in which 95% of the values 
will be found (mean difference ± 1.96 x SD). A small mean difference between two 
methods does not imply that they are interchangeable. If a mean difference of  
3 mL/min/1.73m2 is found between an estimated and reference GFR but the limits 
of agreement were 54 mL/min/1.73m2 below and 47 mL/min/1.73m2 above, the 
estimated GFR (usually a new method) would be unacceptable for clinical purposes, 
since one would not be able to detect small changes in GFR (for example 10 mL/
min/1.73m2).
Comparing methods to estimate GFR in children, Bland-Altman plots are entering 
common use and the bias and imprecision have been calculated in several studies. 
It is interesting to speculate on the predictive performance if, for example, Schwartz 
et al. had used Bland-Altman plots in stead of the correlation coefficient in order to 
validate that formula. 
In general, Bland-Altman plots should be created and/or the predictive performance 
(i.e. bias and imprecision) should be calculated, and it is out of date to plot the 
estimated value against the reference value, and state the correlation coefficient. 
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CONCLUSION AND FINAL 
REMARKS
For many years it was common, when 
assessing renal function in children, to 
determine the inulin clearance (urinary 
or plasma clearance) by administering 
inulin by continuous intravenous infusion. 
Determination of the plasma clearance of 
inulin by the single injection method was less 
common, since for an accurate determination 
10-12 blood samples were required. This 
number of blood samples is stressful and 
inconvenient for children. Recently, the 
number of blood samples required for the 
inulin single injection method has been 
reduced by the introduction of limited and 
optimal sampling strategies. The inulin single 
injection method with blood samples taken at 
10, 30, 90 and 240 minutes after administration 
of inulin and calculation of GFR by Bayesian 
analysis with appropriate pharmacokinetic 
software like MW/Pharm, is accurate and 
convenient for children. This method is 
easy enough to apply in any hospital, but 
its utilization is limited since it is not very 
practical to use every day. For daily practice 
GFR in children can be estimated by using 
a formula based on the ratio of creatinine 
plasma concentration and body height, 
multiplied by a constant k, whose value is 
assessed locally. Based on  
our studies we recommend the formula with  
k = 40 (Morris et al.) as a good starting point.    
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In Chapter 1 the advantages and 
disadvantages of several methods to 
determine GFR in children for daily practice 
and in a clinical research setting are described. 
Also, the practical aspects of endogenous 
(creatinine and cystatin C) and exogenous 
(inulin, radio-isotopes and iohexol) markers  
are discussed. 
In Chapter 2 we describe the development 
and the validation of several sampling 
strategies with a reduced number of samples 
to predict the inulin plasma clearance in 
pediatric patients using the inulin single 
injection method. First a population 
pharmacokinetic model for inulin was 
developed for the index data set (n=100) 
and included the variables BSA (body surface 
area) and HUS (hemolytic uremic syndrome). 
Then optimal sampling times were selected 
and validated in the validation data set 
(n=54). Strategies with 2 to 4 samples, which 
should include a sample at 240 min after 
administration of inulin, produced an accurate 
prediction of inulin clearance in the validation 
CHAPTER 8 Summary
Renal function tests are important to evaluate 
the progression of kidney disease and to 
monitor renal function during drug treatment. 
For the assessment of renal function the 
mechanisms responsible for the formation 
of urine, namely filtration, reabsorption and 
secretion, must be taken into consideration. 
The excretion of endogenous and exogenous 
substances is mainly regulated by glomerular 
filtration. Glomerular filtration rate (GFR) is 
considered the most important parameter to 
evaluate renal function and it is affected by 
most kidney diseases.
For children’s convenience it is important that 
the determination of GFR can be performed 
in a short time window with minimal 
intervention. On the other hand it is important 
that the test shows a high accuracy. In general, 
tests that are most accurate are also those that 
are most elaborate and costly. 
The aim of this thesis was to develop a simple, 
practical, convenient and accurate method 
to determine the glomerular filtration rate 
adapted to the specific requirements of 
children.   
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data set (bias < 3% and not significantly different from zero, imprecision < 15%). 
Even 1 blood sample at 240 min showed an acceptable performance, however 
there is no room for errors (pre-analytical or analytical errors). The proposed 
strategies with 2 - 4 blood samples (10 / 30 / 90 / 240 min, 10 / 30 / 240 min, 10 / 
90 / 240 min, 30 / 90 / 240 min and 90 / 240 min) are practical and convenient to 
children and can be applied to determine the inulin plasma clearance in children.
In Chapter 3 the inulin plasma clearance determined by the single injection 
method is compared with the reference method (continuous infusion method) 
in 24 pediatric patients. The inulin plasma clearance determined by the single 
injection method with 4 blood samples was on average 9.7 mL/min/1.73m2 higher 
than the clearance determined with the continuous infusion method (95% CI: 5.3; 
14.2). The difference between both methods was smaller at lower GFRs and it was 
considered acceptable for clinical practice. As a consequence the determination 
of the inulin plasma clearance with continuous infusion, which was applied as 
the standard method to determine GFR in children for many years in the Sophia 
Children’s Hospital, can be replaced by the inulin single injection method. The 
last method is less time-consuming and more convenient since no overnight 
hospitalization is required.  
In Chapter 4 the validation of the inulin single injection method with a limited 
number of blood samples (10 / 30 / 90 / 240 min) in 48 pediatric patients using 
the pharmacokinetic program MW/Pharm is reported. In patients with GFR < 75 
mL/min/1.73m2 the mean difference between the inulin plasma clearance based 
on 4 blood samples and the reference clearance (based on 11 blood samples) was 
not statistically significant. For GFR > 75 mL/min/1.73m2 a small bias was observed 
(mean difference: -5.92 mL/min/1.73m2; 95% confidence interval: -10.2; -1.68 mL/
min/1.73m2). The pharmacokinetic program MW/Pharm, which is available in nearly 
all hospital pharmacies, can be used to calculate the inulin plasma clearance in 
children determined by the single injection method with 4 blood samples. In this 
way, the optimized method can easily be implemented in every Dutch hospital. 
 
For daily practice the glomerular filtration rate in children can be estimated by GFR 
= k x BH / Pcr (BH: body height (cm); Pcr: plasma creatinine concentration (μmol/L)). 
In Chapter 5 the predictive performance of formulae to estimate GFR in children is 
evaluated. In 48 children (aged from 5 - 18 years; GFR: 7 - 158 ml/min/1.73m2) GFR 
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estimated by formulae was compared with the 
inulin plasma clearance. The formula with a k 
value of 41.2 or 40 showed the best predictive 
performance. Introduction of more patient 
factors (age, body surface area, body weight 
and gender) resulted in an algorithm, that did 
not improve the predictive performance. 
However, the performance of the formulae 
is closely linked with the method, which was 
used for an accurate determination of GFR 
(reference method) and the population of 
patients. As a consequence it is recommended 
to assess the optimal value for k locally.  
In Chapter 6 the use of cystatin C as an 
endogenous marker for GFR is described. 
Cystatin C is a relatively new marker for GFR 
and has been suggested as an alternative for 
creatinine. We applied the renal extraction 
ratio of cystatin C to evaluate whether 
cystatin C is useful to estimate GFR. The 
renal extraction ratio is a parameter for 
renal function and expresses the glomerular 
filtration and tubular handling (tubular 
secretion and / or reabsorption) of a 
substance. The renal extraction of cystatin C 
was compared with that of 125I-iothalamate 
in 40 hypertensive adult patients. The mean 
difference between the renal extraction ratio 
of cystatin C and that of 125I-iothalamate was 
0.002 (95% confidence interval :-0.036 to 0.032). 
However, the limits of agreement were large  
(-0.271 and 0.267) and not acceptable. Therefore, 
the use of cystatin C to estimate GFR is limited 
and as a consequence it cannot replace the 
traditional endogenous marker creatinine.   
In conclusion, the inulin single injection 
method with blood samples taken at 10, 30, 90 
and 240 minutes after administration of inulin 
and calculation of GFR by Bayesian analysis 
with appropriate pharmacokinetic software 
like MW/Pharm, is an accurate method to 
determine GFR in children. This method is also 
convenient for children and easy enough to 
apply in any hospital. For daily practice GFR in 
children can be estimated by using a formula 
based on the ratio of creatinine plasma 
concentration and body height, multiplied by 
a constant k, whose value is assessed locally. 
The formula with k = 40 (Morris et al.) is a good 
starting point to estimate GFR in children.
This thesis describes how the method for 
the determination of GFR in childeren is 
simplified and is an exellent example how to 
solve an important clinical problem in a multi-
disciplinary fashion.
CHAPTER 8 Summary
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het bloed gevolgd. Het is gebruikelijk om de 
nierfunctie bij kinderen gestandaardiseerd 
uit te drukken in ml/min/1.73m2 lichaams-
oppervlakte, zodat verschillen tussen kleine en 
grote kinderen worden opgeheven.
Voor het welzijn van kinderen is het belangrijk 
dat de test voor het bepalen van de 
nierfunctie kan worden uitgevoerd in een kort 
tijdsbestek met minimale belasting.  
Aan de andere kant is het belangrijk dat de 
test een hoge nauwkeurigheid heeft. In het 
algemeen zijn de meer nauwkeurige testen 
minder patiëntvriendelijk.
Het doel van dit proefschrift is het 
ontwikkelen van een eenvoudige, praktische, 
patiëntvriendelijke en nauwkeurige methode 
voor het bepalen van de nierfunctie bij 
kinderen. 
In Hoofdstuk 1 worden de voor- en nadelen 
van verschillende methoden voor het 
bepalen van de nierfunctie bij kinderen 
beschreven, zowel voor de dagelijkse klinische 
praktijk als voor een onderzoeksomgeving. 
Eveneens worden de praktische aspecten van 
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Het testen van de nierfunctie is belangrijk 
voor het evalueren van de voortgang van een 
nierziekte en het volgen van de nierfunctie 
tijdens behandeling met geneesmiddelen. 
Voor het bepalen van de nierfunctie kunnen 
verschillende stoffen (markers) worden 
gebruikt. Markers voor de nierfunctie kunnen 
worden onderverdeeld in lichaamseigen 
en niet-lichaamseigen stoffen. Inuline, 
een groot suikermolecuul, wordt gezien 
als ideale marker. Het behoort tot de niet-
lichaamseigen markers. Kreatinine en cystatine 
C zijn voorbeelden van lichaamseigen 
markers. Kreatinine wordt in de dagelijkse 
praktijk gebruikt voor het schatten van de 
nierfunctie op basis van een formule. Voor 
het nauwkeurig bepalen van de nierfunctie, 
zoals gewenst is in bijvoorbeeld een 
onderzoeksomgeving, is deze methode niet 
geschikt. De klassieke methode voor het 
nauwkeurig bepalen van de nierfunctie is 
gebaseerd op het toedienen van een bekende 
dosis inuline en het verschijnen van inuline in 
de urine. Bij de alternatieve methode wordt 
na toediening het verdwijnen van inuline uit 
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lichaamseigen (kreatinine en cystatine C) en niet-lichaamseigen (inuline, radio-
isotopen en iohexol) markers voor het bepalen van de nierfunctie bediscussieerd.
In Hoofdstuk 2 wordt het opstellen en testen van diverse bemonsteringsschema’s 
voor het bepalen van de nierfunctie bij kinderen beschreven. Hierbij werd 
uitgegaan van de inuline eenmalige injectie methode. Inuline werd als eenmalige 
gift via de bloedbaan gegeven en twaalf bloedmonsters werden in een tijdsbestek 
van 240 minuten afgenomen. Op grond van de inuline concentratie in de 
afgenomen bloedmonsters, werd de nierfunctie berekend. Het doel van dit 
onderzoek was om het aantal af te nemen bloedmonsters te verminderen. Hiervoor 
werd een populatie farmacokinetisch model voor inuline ontwikkeld en werden 
optimale bemonsteringstijdstippen vastgesteld. Vervolgens werden  diverse 
bemonsteringsschema’s getest in een data set met gegevens van 54 kinderen. 
Bemonsteringsschema’s met 2 tot 4 bloedmonsters, inclusief een bloedmonster  
240 minuten na toedienen van inuline, leverde een nauwkeurige voorspelling 
van de nierfunctie op. Zelfs 1 bloedmonster op 240 min leverde een acceptabel 
resultaat op, maar het gebruik van 1 bloedmonster is erg risicovol. 
De bemonsteringsschema’s met 2 - 4 bloedmonsters (10 / 30 / 90 / 240 min,  
10 / 30 / 240 min, 10 / 90 / 240 min, 30 / 90 / 240 min, en 90 / 240 min) zijn 
praktisch en kindvriendelijk, leveren een nauwkeurig resultaat op en kunnen  
goed worden gebruikt voor het bepalen van de nierfunctie bij kinderen. 
In Hoofdstuk 3 wordt de nierfunctie bepaald met de inuline eenmalige injectie 
methode, vergeleken met de continue infusie methode. De continue infusie 
methode was lange tijd de standaard methode voor het bepalen van de nierfunctie 
bij kinderen in het Sophia Kinderziekenhuis. De methode bestaat uit het toedienen 
van inuline via de bloedbaan tot een constante concentratie inuline in het bloed is 
bereikt. Voor deze methode moet de patiënt een nacht worden opgenomen, terwijl 
de eenmalige injectie methode in 4 uur kan worden uitgevoerd. Bij 24 kinderen werd 
de inuline eenmalige injectie methode vergeleken met de continue infusiemethode. 
De nierfunctie bepaald met de eenmalige injectie methode met 4 bloedmonsters 
(10 / 30 / 90 / 240 min) was gemiddeld 9.7 mL/min/1.73m2 hoger dan de nierfunctie 
bepaald met de continue infusie methode. Het verschil tussen beide methoden 
was kleiner bij slechtere nierfunctie en was acceptabel in relatie tot de klinische 
praktijk. Op basis van deze resultaten kan de continue infusie methode worden 
vervangen door de inuline eenmalige injectie methode. Deze laatste methode is 
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kindvriendelijker en kost minder tijd, omdat 
geen opname gedurende de nacht is vereist.   
In Hoofdstuk 4 wordt het testen van de 
inuline eenmalige injectie methode met 
een verminderd aantal bloedmonsters en 
gebruik makend van het computerprogramma 
MW/Pharm beschreven. Voor het berekenen 
van de nierfunctie aan de hand van de 
inuline eenmalige injectie methode met een 
verminderd aantal bloedmonsters is een 
computerprogramma nodig, dat gebruik 
maakt van het populatie farmacokinetisch 
model van inuline. Het computerprogramma 
MW/Pharm, dat beschikbaar is in bijna elke 
ziekenhuisapotheek, werd hiervoor gebruikt. 
Voor 48 kinderen werd de nierfunctie op 
basis van 4 bloedmonsters (10 / 30 / 90 / 240 
min) berekend met het computerprogramma 
MW/Pharm en vergeleken met de nierfunctie 
gebaseerd op alle bloedmonsters (referentie 
nierfunctie). Bij kinderen met een slechtere 
nierfunctie was er geen verschil tussen de 
berekende nierfunctie met MW/Pharm en 
de referentie nierfunctie. Bij kinderen met 
een matige tot normale nierfunctie werd een 
klein maar acceptabel verschil waargenomen 
(gemiddeld verschil : -5.92 mL/min/1.73m2). 
Op grond van deze resultaten kan het 
computerprogramma MW/Pharm worden 
gebruikt voor het berekenen van de nierfunctie 
bij kinderen bepaald met de inuline eenmalige 
injectie methode met 4 bloedmonsters. Met 
deze gegevens kan de geoptimaliseerde inuline 
eenmalige injectie methode eenvoudig worden 
toegepast in elk Nederlands ziekenhuis. 
In Hoofdstuk 5 wordt het gebruik van 
verschillende formules voor het schatten van 
de nierfunctie bij kinderen beschreven.  
Voor de dagelijkse praktijk is het bepalen 
van de nierfunctie met de inuline eenmalige 
injectie methode niet praktisch en wordt de 
nierfunctie bij kinderen geschat aan de hand 
van een formule, waarbij gebruik gemaakt 
wordt van de lichaamseigen marker kreatinine. 
De formule is gebaseerd op de lichaamslengte 
van het kind, de concentratie kreatinine in  
het bloed en een constante:
Voor de constante zijn in de literatuur 
verschillende waardes beschreven. In 
dit onderzoek werd bij 48 kinderen de 
nierfunctie geschat aan de hand van diverse 
formules en vergeleken met de nierfunctie 
gebaseerd op de inuline eenmalige injectie 
methode. De formule met een constante 
van 41.2 of 40 leverde het beste resultaat op. 
Introductie van meer patiënt factoren naast 
lichaamslengte (leeftijd, lichaamsoppervlakte, 
lichaamsgewicht en geslacht) leidde niet tot 
een beter resultaat. 
Het gebruik van de formules hangt nauw 
samen met de methode, die lokaal werd 
gebruikt voor het bepalen van de nierfunctie, 
en met de patiëntengroep. Om deze reden 
is het aan te bevelen om lokaal de optimale 
waarde voor de constante te bepalen. 
Nierfunctie =
lichaamslengte x constante
concentratie kreatinine
SAMENVATTING
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In Hoofdstuk 6 wordt het gebruik van cystatine C als lichaamseigen marker voor 
de nierfunctie beschreven. Cystatine C is een relatief nieuwe marker en mogelijk 
een alternatief voor kreatinine. In dit onderzoek werd de renale extractie ratio van 
cystatine C bepaald om te beoordelen of cystatine C geschikt is voor het schatten 
van de nierfunctie. De renale extractie ratio van cystatine C werd vergeleken met 
de renale extractie ratio van 125I-iothalamaat (niet-lichaamseigen marker) in  
40 volwassenen met een hoge bloeddruk. Het gemiddeld verschil tussen de renale 
extractie ratio van cystatine C en die van 125I-iothalamaat was klein. Echter, de 
spreiding was erg groot en niet acceptabel. Om deze reden is cystatine C voor het 
schatten van de nierfunctie van beperkte waarde en kan het de traditionele marker 
kreatinine niet vervangen.   
Terugkomend op het doel van dit proefschrift, zoals beschreven staat in het 
begin van deze samenvatting, kan worden geconcludeerd dat de inuline 
eenmalige injectie methode met bloedmonsters afgenomen op 10, 30, 90 en 240 
minuten na toediening van inuline en berekening van de nierfunctie met het 
computerprogramma MW/Pharm, een geschikte methode is om de nierfunctie 
bij kinderen te bepalen. Deze methode is eveneens kindvriendelijk en makkelijk 
toepasbaar in elk ziekenhuis. 
Voor het schatten van de nierfunctie bij kinderen in de dagelijkse praktijk kan 
gebruik worden gemaakt van een formule gebaseerd op lichaamslengte, kreatinine 
concentratie in het bloed en een constante, die lokaal is vastgesteld. De formule 
met als constante k = 40 is een goed startpunt voor het schatten van de nierfunctie 
bij kinderen.    
Tot slot, kan worden opgemerkt dat met dit onderzoek de methode voor het 
nauwkeurig bepalen van de nierfunctie bij kinderen sterk is vereenvoudigd, wat 
zowel voor het kind als voor degene die de test uitvoert voordelen heeft. Tevens 
is het onderzoeksproject een mooi voorbeeld van hoe een belangrijk klinisch 
probleem met een multidisciplinaire aanpak kan worden opgelost. 
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